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Resumo 
 
A dor é definida pela Associação Internacional do Estudo da Dor (IASP) como 
"uma experiência sensorial e emocional desagradável associada a um dano tecidual 
real ou potencial ou descrita em termos de tal dano", que pode ter um papel protetor 
(dor nociceptiva e inflamatória), ou pode ser mal-adaptativa (dor crónica). 
A amilina, um membro da família de peptídeos relacionados com o gene da 
calcitonina, também conhecida como polipeptídeo amilóide, é um péptido com 37 
aminoácidos segregado pelas células β-pancreáticas. Esta hormona é segregada 
simultaneamente com a insulina, em resposta à ingestão de nutrientes. As ações da 
amilina melhor estudadas a concentrações plasmáticas fisiológicos são na inibição da 
ingestão de alimentos e do esvaziamento gástrico. Em consequência disso, esta 
hormona está a ser usada em co-terapia com insulina em pacientes diabéticos nos EUA 
e é objeto de estudos clínicos de terapias para a redução do peso. O papel da amilina 
na nocicepção tem sido estudado recentemente, no entanto, as investigações nesta 
área não são suficientes e os resultados obtidos são muitas vezes contraditórios. 
Inicialmente foram descritos locais de ligação de amilina em áreas do cérebro 
envolvidas na nocicepção e a sua presença foi também detetada em gânglios 
raquidianos dorsais do rato (DRG), sugerindo um papel sensorial deste neuropeptídeo. 
Após estas descobertas interessantes, alguns grupos focaram-se no estudo do papel da 
amilina na nocicepção e sugeriram que este péptido pode estar envolvido na fase 
inicial de inflamação e que pode ter um papel excitatório em condições fisiológicas. 
Por conseguinte, Gebre Medhin e os seus colegas [2] demonstraram que a depleção 
genética da amilina produziu um fenótipo em que os ratinhos eram mais tolerantes à 
estimulação nóxica. Por outro lado, resultados recentes obtidos pelo nosso grupo de 
investigação mostraram que a administração de amilina em animais com dor 
inflamatória crónica produziu um efeito analgésico. Além disso, o nosso grupo também 
observou que a administração de amilina no teste de formalina em rato modulou o 
comportamento de dor manifestado durante a interfase e a fase de dor sustentada. Os 
nossos resultados indicam que o efeito da amilina na dor parece variar de acordo com 
a natureza do estímulo nóxico (aguda/crónica, a origem inflamatória/origem de uma 
lesão do nervo) e com a via de administração (sistémica/central). Estes resultados 
sugerem um papel importante de amilina na nocicepção. 
O estudo apresentado nesta tese de mestrado teve como objetivo esclarecer o 
efeito da amilina no sistema nociceptivo por comparação de respostas 
comportamentais e neuro-químicas entre ratinhos sem o gene da amilina (ratinhos KO) 
e ratinhos de estirpe selvagem (ratinhos WT). Ambos os grupos de animais foram 
sujeitos a testes de dor aguda e a três diferentes modelos de dor: dor visceral, dor 
inflamatória crónica e dor neuropática. 
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Os testes de dor aguda realizados em ratinhos naïve sugerem que os ratinhos 
KO são geralmente mais sensíveis aos estímulos mecânicos do que os ratinhos WT. 
Foram observadas algumas diferenças nos resultados obtidos pelos testes térmicos de 
dor aguda, uma vez que no teste de Hargreaves não houve diferenças significativas 
entre os dois grupos de animais, indicando que a falta da amilina em animais KO não 
causa alterações na sensibilidade ao calor, ao contrário do teste de Cold plate em que 
os animais KO toleraram melhor o frio nóxico do que os animais WT. 
A indução de dor inflamatória utilizando o Adjuvante Completo de Freund 
produziu uma resposta imunitária forte, que resultou numa reação artrítica localizada, 
resultando no desenvolvimento de uma inflamação grave na pata, de alodínia 
mecânica e hiperalgesia térmica. Uma vez que as patas ipsilaterais de ratinhos WT 
apresentaram diferenças significativas em comparação com as patas não inflamadas 
contralaterais, ao contrário do observado para as patas ipsilaterais de ratinhos KO, 
pudemos concluir que os ratinhos WT são mais sensíveis aos estímulos nóxicos 
aplicados. 
A indução da dor neuropática foi realizada usando um modelo de lesão parcial 
do nervo ciático onde dois dos seus três ramos são ligados e axotomizados, 
denominado SNI (do inglês spared nerve injury) e resultou em alodínia e hiperalgesia 
intensas na região lateral da pata posterior, que recebe inervação do ramo do nervo 
ciático que foi deixado intacto, a qual se encontra hipersensível. Os resultados 
observados em testes de dor aguda sugerem que os ratinhos KO foram menos 
sensíveis aos diferentes estímulos aplicados, mostrando menos sinais de dor 
neuropática. Estes resultados são suportados pela quantificação de c-Fos, um gene de 
expressão imediata, que é expresso pelos neurónios rapidamente em resposta a 
estímulos. Assim, ratinhos WT expressaram mais c-Fos do que ratinhos KO, sugerindo 
que mais neurónios nociceptivos específicos da medula espinhal foram ativados em 
ratinhos WT. 
A indução da dor visceral foi conseguida através de uma injeção intraperitoneal 
de ácido acético. As respostas nociceptivas foram medidas através da contagem do 
número de contrações em intervalos de 5 minutos, durante vinte minutos. Foi 
observado um efeito temporal e os ratinhos KO contraíram mais vezes o abdómen do 
que os ratinhos WT no período entre os 5 e os 15 minutos apos injeção, sugerindo um 
papel anti-nociceptivo da amilina na dor visceral. Estes resultados são suportados pela 
quantificação de neurónios positivos para o c-Fos na medula espinhal, uma vez que se 
observou que animais KO expressaram significativamente mais c-Fos do que animais 
WT. 
Para avaliar alterações na densidade neuronal em gânglios raquidianos, foi 
realizada a coloração por hematoxilina e eosina, sendo o número total de neurónios 
quantificado. Contudo, não houve diferenças significativas entre os dois grupos 
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animais. Por outro lado, a medição das áreas neuronais mostrou que os ratinhos KO 
têm uma tendência para ter mais neurónios de pequeno tamanho (<600 µm2) e têm 
significativamente menos neurónios de grande área (>1200 µm2), em comparação com 
ratinho WT. 
Para avaliar alterações nas populações de nociceptores entre ratinhos WT e KO, 
os níveis de expressão de CGRP, um marcador bem conhecido de nociceptores do tipo 
C péptidergicos, foram quantificados. Não foram detetadas diferenças significativas na 
percentagem de neurónios que expressam CGRP em DRGs da região L4 e L5. 
Resumindo, o papel da amilina na nocicepção parece variar dependendo do 
modelo de dor em causa. Além disso, a falta da amilina em ratinhos KO parece 
envolver alterações no sistema nociceptivo em populações neuronais especificas dos 
gânglios raquidianos. 
 
Palavras-chave: amilina, nocicepção, dor visceral, dor inflamatória, dor crónica, 
alodínia, hiperalgesia, medula espinhal, c-Fos, DRG, CGRP. 
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Abstract:  
 
 Pain is defined by the International Association for the Study of Pain (IASP) as 
"an unpleasant sensory and emotional experience associated with actual or potential 
tissue damage, or described in terms of such damage", which may have a protective 
role (nociceptive and inflammatory pain), or can be maladaptive (chronic pain).  
Amylin, a member of the calcitonin gene-related peptide family, also known as 
islet amyloid polypeptide, is a 37 amino-acid-long secretory product of pancreatic β-
cells. This peptide hormone is secreted simultaneously with insulin, in response to 
nutrient ingestion. The best studied actions of amylin at physiological plasma 
concentrations are on inhibition of food intake and gastric emptying. Thus, this 
hormone is being used in co-therapy with insulin in diabetic patients in the US, and is 
employed in clinical studies for weight reduction. Lately, amylin’s role in nociception 
has been studied, however the investigations in this area are still not sufficient and the 
results obtained are often contradictory. At first, amylin’s binding sites have been 
described in brain areas involved in nociception and its presence has also been 
detected in rat’s dorsal root ganglions (DRG), suggesting a sensorial role for this 
neuropeptide. After these interesting findings, some groups focused on amylin’s role in 
nociception and suggested that this peptide could be involved in the initial phase of 
inflammation and that it could have an excitatory role under physiological conditions. 
Accordingly, Gebre Medhin and his colleagues [2] have shown that amylin genetic 
depletion produced a phenotype in which mice are more tolerant to noxious 
stimulation. On the other hand, recent results obtained by our research group show 
that chronic subcutaneous amylin administration in animals with chronic inflammatory 
pain has analgesic effects. Additionally, our group has also observed that amylin 
administration in the rat formalin test modulates the pain behavior manifested at the 
interphase and in the sustained pain phase. Our data indicates that amylin’s effect on 
pain seems to fluctuate according to the nature of the noxious stimulus (acute/chronic, 
inflammatory origin/ origin in a nerve lesion) and to the route of administration 
(systemic/spinal). Overall, these results suggest an important role of amylin in 
nociception.  
The study presented in this master thesis aimed at clarifying the effect of 
amylin in the nociceptive system by comparing the behavioral and neurochemical 
responses of mice with a general ablation of the amylin gene (amylin knock-out, KO, 
mice) with their wild-type (WT) littermates. Both mice genotypes were subjected to 
acute pain and to three different models of ongoing pain: visceral pain, chronic 
inflammatory pain and neuropathic pain.  
The acute pain tests performed on naïve mice suggested that amylin KO mice 
are generally more sensitive to mechanical stimuli than WT mice. Some dissimilarity in 
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the results were noted when analyzing both thermal acute pain tests, since the 
Hargreaves test showed no significant differences between both animals groups, 
indicating no changes in noxious heat sensitivity due to amylin’s lack, contrarily to the 
cold plate test, which suggested that KO animals tolerate better the noxious cold than 
WT animals.  
The induction of inflammatory pain using complete Freund’s adjuvant (CFA) 
elicited a strong immune response that resulted in a localized arthritic reaction, since 
mice developed a severe paw inflammation, mechanical allodynia and thermal 
hyperalgesia. As WT ipsilateral hind paws presented significant differences to non-
inflamed hind paws, contrarily to what was observed in KO ipsilateral hind paws, we 
could conclude that WT-CFA inflamed mice were generally more responsive to the 
noxious stimuli applied. 
Induction of neuropathic pain was performed using the spared nerve injury 
(SNI) model and resulted in long-lasting and intense allodynia and hyperalgesia in the 
lateral surface of the hind paw receiving innervation from the spared hypersensitive 
branch of the injured sciatic nerve. The behavior observed in the neuropathic animals 
in response to acute pain tests suggested that KO mice were less sensitive to the 
different applied stimuli, showing less signs of neuropathic pain. These results were 
supported by the quantification of c-Fos immunolabeling, an immediate early gene 
that is rapidly expressed by neurons in response to stimulation. Thus, WT mice showed 
more c-Fos positive neurons than KO mice suggesting that more spinal cord 
nociceptive-responsive neurons were activated in WT SNI-mice. 
Induction of visceral pain was done by an intraperitoneal injection of acetic 
acid. The nociceptive response was measured by counting the number of writhes in 5 
minute time-periods for 20 minutes. A time effect was noted and KO animals had in 
total more writhes than WT animals between 5 and 15 minutes post injection, 
suggesting an anti-nociceptive role of amylin in visceral pain. These results were 
supported by quantification of the number of c-Fos positive spinal cord neurons after 
acetic acid injection, since amylin KO animals expressed significantly more c-Fos than 
WT animals.  
To assess changes on the neuronal density in dorsal root ganglia (DRG), a 
hematoxylin and eosin staining was performed and the total number of neurons was 
quantified, but no significant variations were detected when comparing WT and KO 
animals. However, the measurement of the cell body area showed that KO animals 
tended to have more small-sized neurons (<600 µm2) and had significantly lesser 
amounts of large-sized neurons (>1200 µm2), comparing to WT animals.  
To assess changes in nociceptors populations between KO and WT mice, we 
also quantified the expression of calcitonin gene-related peptide (CGRP), a known 
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marker of peptidergic C nociceptors in DRG. We observed no significant differences in 
the percentage of neurons which expressed CGRP in L4 and L5 DRGs.  
Overall, amylin’s role in nociception seems to vary depending on the model of 
pain. Moreover, the lack of amylin in KO mice seems to involve alterations in the 
nociceptive system in specific populations in the DRG.  
 
Key-words: amylin, nociception, visceral pain, inflammatory pain, chronic pain, 
allodynia, hyperalgesia, spinal cord, c-Fos, DRG, CGRP. 
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Nomenclature  
 
BDNF Brain derived neurotrophic factor 
CFA Complete Freund’s Adjuvant 
CGRP Calcitonin gene related peptide 
CMH C mechano-heat nociceptors 
CNS Central nervous system 
CTR Calcitonin receptor  
DAB 3,3-diaminobenzidine 
DRG Dorsal root ganglia 
GABA γ-aminobutyric acid 
H&E Hematoxylin and eosin 
IAPP islet amyloid polypeptide 
IASP International Association for the Study of Pain 
KO Knock-out 
L3-L6 Lumbar 3 until Lumbar 6 
L4 Lumbar 4 
L5 Lumbar 5 
NGF Nerve growth factor  
NHS Normal horse serum 
NS Nociceptive specific 
NSAID Non steroidal inflammatory drugs 
NSS Normal swine serum 
NT-3 Neurotrophin 3 
PBS Phosphate-buffered saline 
PBST Phosphate-buffered saline with triton-X 100 
PCR Polymerase chain reaction  
PNS Peripheral nervous system 
PWL Paw withdrawal latency  
RAMP Receptor activity modifying protein 
sCT Salmon calcitonin 
SNI Spared nerve injury 
SNL Spinal nerve ligation 
SP Substance P 
TRPM8 Transient receptor potential melastatin 8 
TRPV1 Transient receptor potential vanilloid-1 
T5 Thoracic 5 
T13 Thoracic 13 
T5-L2 Thoracic 5 until Lumbar 2 
WDR Wide dynamic range  
WT Wild-type 
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Introduction  
 
Nociception 
 
The International Association for the Study of Pain (IASP) defined pain as ‘’an 
unpleasant sensory and emotional experience associated with actual or potential 
tissue damage or described in terms of such damage’’ [3]. Pain can be classified as 
being nociceptive or neuropathic. The first can occur as a result of the noxious 
stimulation of nociceptors localized on skin, viscera and other organs. When pain is 
resultant from a dysfunction or lesion in the nervous system, it is classified as 
neuropathic pain [4]. However, this definition of pain was shown not to be appropriate 
for animals, as it becomes hard to analyze if an emotional experience occurred or not. 
Therefore, Zimmermann defined pain as ‘’an aversive sensorial experience derived 
from a concrete or potential lesion that causes progressive motor and vegetative 
reactions, results in behaviors of evasion and can modify specific behaviors of species, 
including social behavior’’ (1986) [5]. 
Although the pathways of pain perception are not fully described or 
understood, pain is a process of utmost importance since it is a symptom of many 
diseases, being considered as a major cause of demand for health professionals among 
the population in general, as it is very debilitating for the patient. The sensation of pain 
is present in diseases and in medical procedures and its ineffective treatment can lead 
to elevated socio-economic costs [4].  
Besides the non-steroidal anti-inflammatory drugs (NSAIDs), usually prescribed 
to alleviate pain of inflammatory origin, the remaining therapies currently used to 
treat pain are mainly based on the use of narcotic analgesics like morphine, and 
sedative agents which include barbiturates and benzodiazepines. These agents 
promote analgesia, i.e., absence or reduction of pain in response to a noxious stimulus. 
However, these analgesics also produce undesirable side effects, such as depressant 
actions on respiration [6] and circulation, urinary retention [7], pruritus [7], 
constipation as well as possible somnolence or drowsiness [8]. Moreover, narcotic 
analgesics may induce tolerance in patients, as well as dependence. 
It is therefore important to invest in the discovery of new more effective 
therapies that show no significant adverse effects and do not induce tolerance in 
patients, to combat pain.  
From a neurobiological perspective, pain can be classified in three major 
different types: nociceptive pain, inflammatory pain and, finally, pathological pain, as 
summarized in Figure 1 [9].  
The first one, nociceptive pain, is an early-warning physiological protective 
system, essential to detect and minimize contact with damaging or noxious stimuli 
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which can lesion the tissues [9]. This is the pain we feel when touching something too 
hot, cold, or sharp. This kind of pain is concerned with the sensing of noxious stimuli. It 
is associated to the stimulus detection and minimizes the contact with damaging 
stimuli, and so it has a protective role. This protective role demands instantaneous 
attention and action, which occurs by the withdrawal reflex that it activates, the 
intrinsic unpleasantness of the sensation caused, and the emotional anguish it involves 
[9]. Nociceptive pain is, therefore, essential for maintaining the body integrity [9]. 
Inflammatory pain has also an adaptive and protective role. This pain assists the 
healing of the injured body part, since it creates a situation that discourages physical 
contact and movement. The process of inflammatory pain is caused by the activation 
of the immune system by tissue injury or infection [9]. Pain hypersensitivity, or 
tenderness, reduces further risk of damage and promotes recovery. In a surgical 
wound or in an inflamed joint, for example, stimuli that are normally innocuous now 
elicit pain (allodynia). In this condition, an increased perception of noxious stimuli in 
the affected area (primary hyperalgesia) or in the adjacent region (secondary 
hyperalgesia) also occurs [10]. 
At last, there is pathological pain which is not protective, but maladaptive, and 
results from abnormal functioning of the nervous system. This pain is not a symptom 
of disorder but a disease state of the nervous system. It occurs when excessively 
intense or prolonged stimuli induce tissue damage that results in extended discomfort 
and abnormal sensitivity. This may arise spontaneously and is characterized by a low 
threshold to noxious stimuli, causing an exaggerated response to these stimuli, and 
leading to the presence of primary and secondary hyperalgesia, as well as allodynia. It 
is caused by tissue damage-associated inflammation (inflammatory pain), or by central 
or peripheral nerve injury (neuropathic pain) [11]. 
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Figure 1 - Pain classification: Nociceptive pain, Inflammatory Pain and Pathological pain. From [9]. 
 
Animal Pain Models 
  
Since pain plays an important role on actual society, and its ineffective 
treatment can lead to elevated socio-economic costs, it has been object of intense 
research. The major purpose of these studies has been to promote knowledge that will 
be important to treat acute and chronic pain. To study pain’s underlying pathological 
mechanisms, animal models which mimic different human clinical conditions have 
been developed throughout the last decades.  
Inflammatory Pain Models 
In order to understand the mechanisms of persistent pain, animal models of 
inflammatory pain that simulate human clinical pain conditions have been developed. 
The majority relies on the injection of inflammatory agents into the rat or mouse hind 
paw [12]. The main inflammatory agents currently used are carrageenan [13], formalin 
[14], complete Freund’s adjuvant (CFA) and capsaicin [15], although there are more 
agents available.  
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Complete Freund’s adjuvant injection is a model widely used which consists in 
the injection of a mycobacteria in a fatty excipient [16] in the animal’s hind paw, which 
will trigger a strong immune response. This method is known for causing pannus 
formation, cartilage erosion, inflammation and hyperplasia, the same symptoms 
associated with rheumatoid arthritis, an inflammatory autoimmune disorder [17]. 
After CFA injection, the cutaneous inflammation appears within two hours and the 
hyperalgesia and edema are present for at least one or two weeks [17]. It is widely 
considered as a reliable and useful model to study inflammation and nociception in 
both rat and mice, which produces a consistent, localized arthritic reaction with 
associated inflammation-induced nociceptive behavioral changes [18].  
Pathological Pain Models: Neuropathic Pain  
 Neuropathic pain results from trauma in the central (CNS) or peripheral 
nervous systems (PNS), causing allodynia, hyperalgesia and spontaneous pain. There 
are several animal models that mimic human peripheral neuropathic pain, which often 
combine both intact and injured fibers [19]. These models include the spinal nerve 
ligation (SNL) [20] and the spared nerve injury (SNI) models [19]. The last one consists 
on the injury of two of the three branches of the sciatic nerve (the tibial and the 
peroneal nerves) while the third (sural nerve) is left intact. This procedure will induce 
very rapidly hypersensitivity in the skin area adjacent to the denervation [20].  
The SNI has been described as an intense, reproducible and simple model that 
produces long-lasting and intense allodynia and hyperalgesia for about six months as 
well as behavioral changes that can be measured by stimulating the non-injured sural 
nerve skin territory [20]. Acute sensory and pain behavioral tests like the von Frey and 
Cold Plate, respectively, are conducted to measure hypersensitivity to mechanical and 
thermal stimuli and the intensity of pain induced in the animals by the axotomy of the 
tibial and peroneal nerves. Given the similarities to human neuropathic pain and the 
advantages shown by the SNI model, it is highly used for the study of the mechanisms 
involved in the development of neuropathic pain and to test the efficacy of new 
treatments.  
Acute Visceral Pain Models 
 Visceral pain is the most usual form of pain in the clinical setting and one of the 
most relevant reasons for patients to seek medical supervision [21]. It results from 
pain in the internal organs and is described as being vague, poorly defined and more 
similar to a discomfort than a real sense of pain. Visceral pain is usually perceived 
indistinctly in the same site (lower sternal region of epigastrium) no matter what organ 
is involved [22].  
 In order to induce this type of pain in rats or mice, it is usual to perform an 
intraperitoneal injection of a noxious agent [22]. This method is called ‘’the writhing 
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test’’. After the injection of the chemical irritant, the animal will respond with 
characteristic contractions of the abdominal muscles accompanied by a hind limb 
extensor motion. The most frequently used agents for the writhing test have been 
phenylquinone and acetic acid [23].  
Intraperitoneal injection of acetic acid is a well-known noxious chemical visceral 
stimulus in animals that produces the already mentioned abdominal contractions or 
writhes, and also affects the gastrointestinal ileus by inhibiting gastric emptying and 
small intestine transit, which is associated with visceral pain [24]. 
 
Nociceptors 
 
The PNS neurons responsible for the detection and transmission of noxious 
stimuli are known as nociceptors [25]. The nociceptor has four major functional 
components: the peripheral terminal that transduces external stimuli and initiates 
action potentials, the axon that conducts action potentials, the cell body that controls 
the identity and integrity of the neuron and is localized in sensory ganglia, and the 
central terminal which forms the presynaptic element of the first synapse in the 
sensory pathway in the CNS (Figure 2) [26]. Stimuli arising from the face and head will 
be sensed by nociceptors with their cell bodies located in trigeminal sensory ganglia 
while stimuli in the remaining parts of the body will be conducted to cell bodies 
located in dorsal root ganglia (DRG). 
 
 
Figure 2 - Schematic drawing of nociceptor's structure. It is represented the location of the cell body of a nociceptor 
responsible for detecting stimuli in all parts of the body except the face and head. From:  [25] 
Each nociceptor structure has an essential role in the perception and 
transduction of the stimulus. The cell body is necessary to maintain the other regions 
of the cell and is located in the ganglia of the spinal cord dorsal roots, as already 
mentioned. The axon detects peripheral stimuli, transduces their energy into an 
electrical signal and conducts the action potential to the synaptic terminal where the 
information is transmitted to the primary sensory area. Thus, stimuli arising from 
trigeminal ganglia will be conveyed into the trigeminal nucleus while stimuli from DRG, 
arising from any part of the body except the face and head, will convey into the dorsal 
horn of the spinal cord. These stimuli can be thermal, mechanical or chemical from 
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different parts of the organism. The release of transmitters at the synaptic terminal is 
subject to modulation by agents released by other neurons and possibly by glial cells 
[25].  
Nociceptors can be broadly divided into two classes: one class has small-
diameter cell bodies and slowly conducting, unmyelinated axons (C fibers), whereas 
the other class has medium-diameter cell bodies and faster conducting, lightly 
myelinated axons (Aδ fibers) [27]. There are also Aβ fibers which transmit non-
nociceptive information [4]. These different fibers are divided into three big groups, in 
result of their different conduction velocities, fiber diameter and myelination, as it is 
shown in Table 1:  
 
Table 1 -  Classification of cutaneous sensitive fibers 
Fiber Myelination Conduction 
velocity 
Fiber 
Diameter 
Aβ Thick  30-100 
m/s 
>10 µm 
Aδ Thin  12-30 m/s 2-6 µm 
C Absent 0,5-2 m/s  0,4-1,2 
µm 
  
 Nociceptors can also be further divided into three groups according to their 
neurochemistry: peptidergic C nociceptors, non peptidergic C nociceptors and Aδ 
nociceptors. All of them have glutamate, the most abundant excitatory neuropeptide. 
However, the peptidergic C nociceptors also express substance P (SP) and the 
calcitonin gene related peptide (CGRP). These CGRP-containing neurons are activated 
by chemical, thermal, and high-threshold mechanical stimuli, and innervate essentially 
all peripheral tissues [28]. They also send primary afferent input to nociceptive and 
viscerosensitive neurons in the dorsal horn, trigeminal nucleus caudalis, or nucleus of 
the solitary tract that project to the brainstem, amygdala, hypothalamus, and thalamic 
nuclei, which in turn transmit these inputs to the somatosensory and insular cortexes 
[28]. This group of nociceptors relies on neuronal growth factor (NGF) for developing 
and survival.  
The second group of nociceptors (non peptidergic C nociceptors) does not have 
peptides and depends on brain derived neurotrophic factor (BDNF) for their 
development and survival. This later type of nociceptors can be identified for the 
presence of specific isolectins, purinergic receptors or other specific enzymes. The final 
group, Aδ nociceptors, relies on neurotrophin-3 (NT-3) and BDNF and is easily 
recognized by the presence of specific neurofilaments [4]. 
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Responses to stimulus 
 As mentioned above, Aβ fibers are responsible for sensing innocuous stimulus, 
like vibration and pressure. Under physiological conditions, C and Aδ fibers conduct 
nociceptive information [4]. When a noxious stimulus is applied, Aδ fibers are 
responsible for the immediate acute pain, exhibiting a high conduction velocity of the 
stimulus. On the other hand, C fibers are responsible for a more diffuse delayed pain 
sensation, as these fibers exhibit a lower conduction velocity and diameter [4].  
 Aδ fibers can be divided into type I and type II Aδ fibers [4]. Type I fibers 
respond mostly to mechanical stimulus, but can also respond to chemical and thermal 
stimulus above 53oC [29]. Type II Aδ fibers are insensible to mechanical stimuli, but 
respond to lower thermal stimuli than Aδ fibers type I.   
 C fibers can be divided according to the noxious stimulus that activates them. 
Many of them are polymodal, so they respond to all different stimuli (mechanical, 
thermal and chemical) [27]. However, some C-nociceptors are only sensitive to thermal 
or mechanical stimulus, or to both [4]. 
The C fibers which are simultaneously sensitive to mechanical and thermal 
stimuli are known as C mechano-heat nociceptors (CMH) and are activated by a range 
of pressures from 30 to 17 mN in human and mice and by temperatures around 39-
51oC [30]. Moreover, there are other types of C nociceptors that are insensitive to 
noxious mechanical and heat stimuli, known as silent nociceptors. These nociceptors 
are present in skin, viscera and joints. In case of inflammation, where there is release 
of histamine or other substances, these C silent nociceptors are capable of being 
activated by noxious stimuli, exhibiting a decrease in their activation threshold [31]. 
Central projections of nociceptors  
The spinal cord consists of a gray inner zone covered by white matter. This gray 
zone is divided in ten laminae, which are anatomically and electrophysiological distinct 
[32]. The lamina I (or marginal zone) is the more superficial region of the dorsal horn, 
which extends to lamina VI. The ventral horn comprises laminae VII-IX and the center 
canal is surrounded by lamina X (Figure 3).  
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Figure 3 - Illustration of a lumbar 4 (L4) cross section of the mouse spinal cord. Left: Nissl staining of a L4 cross 
section of the mouse spinal cord. Right: respective atlas schematic drawing from [33]. 
The central projections of the different types of nociceptor are distributed 
differentially in the spinal cord, occupying different areas and, therefore, different 
laminae [32]. Aβ nociceptors, responsible for transmitting innocuous information, 
terminate in laminae III and IV. They also terminate in lamina V, as well as Aδ and C 
fibers, where convergent non-noxious and noxious inputs are received [32]. Most 
peptidergic C fibers terminate in lamina I and in the most dorsal part of lamina II. On 
the other hand, the non-peptidergic afferents terminate in the mid-region of lamina II. 
Electrophysiological analyses demonstrate that spinal cord neurons within lamina I are 
generally responsive to noxious stimulation (via Aδ and C fibers) (Figure 4). 
Spinal cord neurons can be divided in three major groups, considering their 
functional features. They can be nociceptive specific (NS) therefore responding to 
noxious stimuli only; non-nociceptive, which respond equally to both innocuous and 
noxious stimuli, and wide dynamic range (WDR) neurons, which respond to both 
noxious and innocuous stimuli according to their intensities, so that the response is 
proportional to the intensity of the stimulus [32]. 
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Figure 4 Spinal cord anatomy. NS: nociceptive specific neurons; WDR: Wild-dynamic range neurons. Adapted from: 
[34] 
Neurons in the spinal cord can also be classified as being inhibitory or 
excitatory, or according to the terminus of the axon relatively to the cell body as 
interneurons, propriospinal or projection neurons. Interneurons communicate with 
nearby neurons, propriospinal neurons connect with other regions of the spinal cord, 
in particular the contralateral side, and projection neurons, which are mainly present 
in laminas I, V and X, have long axons and transmit the information from the spinal 
cord to supraspinal regions such as the thalamus and parabrachial area. The thalamus 
activates the pain matrix while the parabrachial area is involved in descending and 
affective modulation [35], facilitating or inhibiting the transmission of painful 
information from the spinal cord.  
During nociceptive transmission, the output of the spinal cord is dependent on 
various spinal mechanisms that can increase or decrease the activity of dorsal horn 
neurons. These mechanisms comprise local excitatory and inhibitory interneurons [34]. 
The inhibitory neurons release γ-aminobutyric acid (GABA) and/or glycine, while the 
preferred neurotransmitter for the excitatory neurons is glutamate.  
Neuronal markers 
 
 The study of the expression of some neuronal markers can be very useful to 
determine the amount of noxious information that is being transmitted to the CNS by 
primary afferent neurons.  
 Quantification of c-Fos expression has been widely used as a marker of 
neuronal excitation [36] and is easily detected by an immunohistochemistry reaction. 
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The immediate early gene c-Fos is quickly expressed by spinal cord neurons following 
noxious stimulation of the body tissues and its laminar distribution is connected to the 
nature of the sensory stimulus [37]. Its transcriptional activation takes place within 
minutes after noxious stimulation and the levels of this proteins reach its peak about 
two hours after stimulation [38] and returns to baseline values after eight to twenty-
four hours after the initial stimulation [39]. It is widely accepted that analysis of c-Fos 
expression may help clarify the central neural activity occurring during the 
development of persistent pain or prolonged inflammatory pain [40]. Indeed, in the 
spinal cord, c-Fos expression is considered specific of neurons activated by noxious 
stimulus while its supraspinal expression may occur independently of a painful 
stimulus [35].    
Another cellular marker related to the nociceptive system is the calcitonin gene 
related peptide (CGRP). CGRP is a 37–amino acid peptide that is a member of the 
calcitonin family and is widely expressed in the PNS and CNS, frequently coexisting and 
interacting with other neurotransmitters [28]. CGRP is known for its vasodilator 
properties and for participating in many central and peripheral pain mechanisms. It is 
upregulated in peripheral nerve injury or tissue inflammation conditions and produces 
sensitization of dorsal horn and trigeminal neurons. CGRP is also known for eliciting 
behavioral pain sensitization [28]. Thus, CGRP is considered a classic marker of 
nociceptive DRG neurons [41], namely, C-peptidergic nociceptors as mentioned above, 
which respond to stimuli that evoke sensations of pain and itch. As for c-Fos, its 
expression is easily detected by an immunohistochemistry reaction. 
Amylin 
 
Amylin, also known as islet amyloid polypeptide, is a 37 amino-acid-long beta-
cell secretory product and the main protein component of the pancreatic islet amyloid 
found in human subjects with type 2 diabetes (Figure 3). Amylin is a product of a gene 
located on chromosome 12. It is transcribed as an 89-aminoacid prepolypeptide, is 
cleaved to form the mature peptide in the β-cells of the pancreas, where it is stored 
along with insulin and C-peptide in the same granules. Amylin is a normal product of β-
cells and is co-released with insulin in a molar ratio of 1 to 100 in healthy non-diabetic 
subjects in response to nutrient stimuli (carbohydrate-and protein-containing meals) 
[42] although this rate is not always constant.  
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Figure 5 - Amino acid sequence of human amilyn. [43] 
Effects of amylin 
Some of amylin’s physiological functions include decrease of appetite [44], 
inhibition of gastric emptying, gastric acid and of secretion of digestive hormones [45], 
therefore amylin controls nutrient appearance in plasma, and plays an important role 
in weight control.  
Amylin presents a regulatory effect on glucose homeostasis, presenting an 
important role on the control of insulin secretion, as it was reported that amylin 
inhibits insulin secretion [46]. While the human amylin peptide readily forms 
aggregates, as mentioned above, rat amylin does not. Therefore, co-therapy 
treatments in type 2 diabetes mellitus patients use a soluble and stable rat amylin 
analogue (pramlintide) to control glycaemia in these patients [47]. Additionally to 
these roles of amylin there are reports of other functions, many of which totally 
unrelated to metabolism control, such as induction of kidney’s epithelial cells 
proliferation [48], development of proximal tubules [49], differentiation of osteoclasts 
and osteoblasts, protection of the gastric mucosa [50], blood pressure regulation 
where it functions as a vasodilator [51], modulation of memory [52] and of motor 
activity [53]. 
Calcitonin and Calcitonin Gene Related Peptide (CGRP)  
It is known that some actions of amylin are identical to the known metabolic 
actions of CGRP and calcitonin. In fact, these peptides belong to the same peptide 
family and possess related structures.  
Amylin’s structure is 50% identical to that of CGRPs, 37 amino acid peptides 
which are widespread neurotransmitters with many potent biological actions [51]. 
CGRP is formed from the precalcitonin gene on chromosome 11 [54] and as result of 
transcription, two different peptides are produced by alternative splicing: procalcitonin 
(in thyroid tissue) and proCGRP (in neural tissue).  
Calcitonin is a 32 amino acid peptide which is produced by thyroid C-cells. 
Calcitonin is synthesized at first as a 132 amino acid precursor molecule and then is 
processed by proteolytic cleavage and by amidation of its carboxy terminal proline 
residue before secretion [55].  
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The gene which encodes calcitonin is also responsible for encoding one of the 
CGRPs, the α-CGRP, which is largely expressed in neural tissue, in both PNS and CNS. α-
CGRP is known to be a potent vasodilator [55]. Cell specific alternate processing of the 
calcitonin/α-CGRP transcripts is the mechanism that regulates the formation of either 
calcitonin or α-CGRP in different cell types.  
Another molecule described as being very similar to calcitonin and α-CGRP is β-
CGRP. This is a product of another gene which is expressed by enteric neurons and it 
differs from α-CGRP by just 3 amino acids in humans [55].  
The peptides just described are extensively distributed in various peripheral 
tissues as well as in the PNS and CNS and induce multiple biological effects. Effects 
such as vasodilatation (CGRP) and inhibition of bone resorption (calcitonin) are shared, 
though with much less potency, by amylin [56].  
Amylin’s receptor  
Earlier reports suggested that amylin acted via CGRP receptors in order to 
achieve its biological effects. Later it was discovered that amylin receptors can be 
reconstituted in cellular systems by co-expressing the calcitonin receptor (CTR) with 
receptor activity modifying proteins (RAMPs). These receptors exhibit high affinity for 
salmon calcitonin, which is recognized as a very potent agonist of amylin receptors, 
while, importantly, CGRP shows much less affinity for these receptors [56]. 
The specific amylin receptor is a heterodimeric complex that consists on the 
association of CTR with one of the three RAMPs, RAMP1, RAMP2 or RAMP3 (Figure 4) 
[57], having high affinity for amylin [58]. It is known that the CTR belongs to the family 
of the G protein-coupled receptors which have 7 transmembrane domains. Analysis of 
CTR transcripts from the porcine kidney epithelial cell line LLC-PK1 has exhibited two 
splice variants, CTR1a and CTR1b, being this last transcript longer due to the presence 
of an additional 48 base pairs coding sequence [59]. These receptors induce the 
accumulation of cyclic AMP, leading to activation of the subordinate signaling cascade. 
As previously stated, RAMPs play an important role in this receptor’s structure, 
offering a mechanism for the ligand specificity variation and regulation of receptor 
function. These proteins have the ability to enhance the affinity of CTR to amylin, 
building up the amylin receptor. When associated with a calcitonin like receptor, 
RAMPs build up the CGRP receptors. 
Six different isoforms of amylin receptors were reported: AMY1(a) 
(CTRa/RAMP1), AMY2(a) (CTRa/RAMP2), AMY3(a) (CTRa/RAMP3), AMY1(b) 
(CTRb/RAMP1), AMY2(b) (CTRb/RAMP2) and AMY3(b) (CTRb/RAMP3), being the most 
common ones AMY1(a) and AMY3(a). CTR(b) displays greater capacity to generate 
RAMP2 AMY receptors than CTR(a) [56]. It was also reported that different RAMPs 
promote different pharmacologic properties and different affinities for the ligands. For 
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Figure 6 - Representation of the amylin receptor structure. Amy: amylin; RAMP: Receptor activity 
modifying proteins; CTR: Calcitonin receptor. Source: [1] 
example, RAMP3 provides a greater affinity for salmon’s calcitonin and amylin while 
RAMP1 increases CTR affinity for mammal’s CGRP and calcitonin [60].  
 
 
 
 
Amylin and Pain  
Some studies have suggested a role of amylin in nociception; however, the 
research in this area has not been sufficient and the results obtained so far are often 
contradictory. Amylin’s binding sites were described in the CNS for the first time by 
Sexton and his colleagues in 1994 [61]. Many of those brain areas are involved in 
nociception such as the nucleus of solitary tract, parabrachial nucleus, hypothalamus, 
the periaquedutal grey, the locus coeruleus and the dorsal raphe, and it is known that 
amylin is transported across the blood-brain barrier to these areas [62]. In fact, 
intracerebroventricular administration of amylin elicited anti-nociceptive effects in 
thermal acute pain, as it increased the time latency in the hot plate test response in 
rats [63]. Moreover, Mulder detected the presence of amylin messenger RNA and of 
the amylin peptide in the rat’s DRG neurons, specifically in C peptidergic nociceptors, 
suggesting a sensorial role for this neuropeptide [64]. They also identified amylin 
expressing fibers in the superficial laminae of the spinal cord [64]. In fact, amylin’s 
expression pattern in rat sensory neurons mimics that of CGRP and substance P 
following noxious stimulation, occurring in small to medium sized nerve cell bodies 
known to receive sensory input. Taking all these findings together, some research 
groups proposed to study amylin’s role in the nervous system, more specifically in 
nociception.  
Mulder and his colleagues continued their research in this area and studied the 
expression of amylin in rat DRGs after induction of inflammatory pain by intradermic 
injection of CFA [65]. Their results showed an increase in amylin expression at early 
time points, suggesting that this peptide could be involved in the initial phase of 
inflammation. Other important finding of this group focused on a neuropathic model in 
rats, which caused a decrease of amylin expression in rat DRGs as well of fiber density 
in the dorsal horn of the spinal cord in the ipsilateral side to the affected limb. This led 
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the Mulder group to consider an excitatory role for amylin under physiological 
conditions [66]. Accordingly, Gebre Medhin and his colleagues have confirmed that 
amylin is a constituent of sensory neurons in mice and its genetic ablation produced a 
phenotype in which mice are more tolerant to noxious stimulation. However, in the 
paw inflammation model induced by CFA, there were no significant differences in the 
ankle diameter between knock-out (KO) mice and wild-type (WT) mice [2]. 
On the other hand, Huang et al demonstrated that amylin, possibly acting on 
AMY1(a/b) or AMY3(a/b) receptors in the spinal cord, induced antinociceptive effects as 
assessed by the acetic acid writhing model of visceral pain. Some studies also show 
anti-nociceptive properties for salmon calcitonin (sCT), a strong amylin receptor 
agonist [67]. Intra-nasal sCT relieved bone pain in patients suffering from malignant 
tumors [68, 69] and improved pain symptoms in patients with knee osteoarthritis [70]. 
When centrally administered, sCT also produced strong antinociceptive effects in the 
tonic pain phase of the formalin test in mice [71]. It is important to note that 
calcitonin’s expression has not been identified in the adult CNS, unlike amylin and 
CGRP [72]. This fact shows the relevance of amylin in pain, suggesting that salmon 
calcitonin may act through amylin’s receptors, rather than via CTR alone, to attenuate 
pain.  
Despite these findings on antinociceptive effects resulting from amylin-receptor 
activation, Bouali and his colleagues were not able to observe significant alterations in 
the nociceptive response when they immersed the rat’s tail in a 49oC water bath after 
central administration of amylin [73].  
Interestingly, recent results obtained by our research group show that amylin 
administration in the rat formalin test modulates the pain behavior manifested at the 
interphase, when auto-analgesia in response to the noxious stimulus takes place, and 
in the sustained pain phase, when inflammatory processes triggered by the chemical 
insult are observed. This effect was dependent on the amylin dose, time of injection 
and route of administration [74]. It was also shown by our group that amylin’s effect 
on pain seems to fluctuate according to the noxious stimulus nature (acute/chronic, 
inflammatory origin/ origin in a nerve lesion). Indeed, while chronic amylin infusion 
was shown to aggravate allodynia to cold stimuli in animals with neuropathic pain [75], 
in animals with chronic inflammatory pain induced by intra-articular CFA injection, 
amylin promoted analgesia [76]. These results propose an important role for amylin in 
nociception.  
It is important to note that studies in this area are not abundant. Although 
some results demonstrated to be contradictory, it is settled that amylin has a role in 
nociception and its study can bring major progresses in pain understanding and 
treatment. Additionally, it is very important to determine whether overlapping or 
related functions of amylin and CGRP are mediated via amylin receptors or via CGRP 
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receptors, and to determine which are the effects specifically related to amylin’s 
peptide and receptor. 
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Objectives  
 
Amylin has been related to nociceptive mechanisms and several studies 
highlight amylin’s role in the nervous system. However, these studies are often 
contradictory and limited, not looking into all the behaviors that are measurable in 
certain pain conditions. Other studies assessed amylin’s role by intracerebroventricular 
administration, but these neglected the fact that amylin might have a direct peripheral 
effect or act at the spinal cord, especially since amylin is produced by DRG neurons. 
Furthermore, there are intriguing results linking amylin lack in KO mice to defective 
nociception [2]. The only study evaluating nociception in amylin KO mice used few pain 
models, did not test the effect of restoring amylin in these animals and did not 
investigate plastic changes in the nociceptive system of these animals. In consequence, 
in this project we intended to assess whether nociception and the nociceptive system 
were altered in animals lacking the amylin gene (KO mice). 
More specifically, in this project we intended: 
1) To investigate changes in the nociceptive behavior in response to noxious 
stimuli in amylin KO mice when comparing to their WT littermates. To achieve 
this goal we induced four different types of pain conditions, namely, animals 
were subjected to acute noxious stimuli, to visceral pain, to chronic 
inflammatory and neuropathic pain. The sensitivity to visceral pain as well as to 
standard acute mechanical and thermal stimuli was tested in naïve animals to 
evaluate whether nociceptive behaviors were altered in animals due to 
amylin´s lack. Animals ongoing inflammatory or neuropathic pain were tested 
with appropriate acute pain tests in order to evaluate the pain behavior 
changes between the two mice genotypes when submitted to the same painful 
condition.  
2) To assess putative changes in the nociceptive system in neuronal populations of 
the DRG of amylin KO mice when comparing to their WT littermates. Thus, the 
number of neurons per area was determined as well as the neuronal density of 
CGRP positive neurons, as a first step towards the investigation of the type of 
sensory fibers that could be altered in KO mice.  
3) To study amylin’s effect on the nociceptive-responsive spinal cord neurons. 
Thus, we analyzed the c-Fos protein expression by immunohistochemistry in 
the dorsal horn of amylin KO and WT mice. This represented an indicator of the 
neuronal activity following noxious stimulation.  
 
FEUP 
Amylin’s role in nociception: study in KO mice 
37 
 
Methods and Materials 
 
Animals and Habituation 
 
 For all experiments, adult amylin KO (IAPP -/-) and WT (IAPP +/+) littermate mice 
with a C57BL/6 background, bred at the Faculty of Medicine of Porto animal house, 
were used. The founder IAPP heterozygous F1 breeding pairs were provided by Prof. 
Thomas Lutz from the University of Zurich, Switzerland, in 2012. All experiments were 
performed with males, except the writhing test where females were used. Ear biopsies 
were used to tag the animal and the tissue was used for genotyping by polymerase 
chain reaction (PCR) analysis. DNA extraction and PCR were performed by the 
Laboratory of Support to Research in Molecular Medicine (LAIMM) at FMUP and are 
described below. 
The 59 C57BL/6 mice used for the experiments were kept under controlled 
conditions (temperature and humidity of 22 ± 2°C and 55 ± 5%, respectively, and a 
light cycle of 12h light / 12 hours darkness).  
 The acclimatization to the conventional animal house area, where tests were 
performed, was of at least 7 days, during which only animal caretakers had contact 
with the animals. Later, the process of habituation began, with simple manipulations 
of the animal, such as picking them up and placing them in the test cages. Animals 
were habituated to the elevated cage with a grid floor used for von Frey and acetone 
tests, to the Hargreaves apparatus cages, as well as to the cold plate test and writhing 
test chambers. Moreover, animals were habituated to freely enter into the metal tube 
restrainer used for the tail pressure test, and to the noise of the Randall Selitto 
equipment used for this test. This preliminary step reduces stress, which is important 
to minimize confusion with stress-induced analgesia, and allows the animals to be 
accustomed to the noise, investigator, handling and manipulation. So, in the 4-5 days 
leading up to the first day of testing and just before the execution of the tests thereof, 
the animals were maintained for about 30 minutes in the testing room without being 
disturbed, and were then transferred to the test chamber where they remained for 
further 30 minutes without any noxious stimulation, in order to acclimatize to the 
conditions of the room and reduce stress and exploratory behaviors. All behavioral 
tests were performed during the light period for all experimental groups, in random 
order, in order to eliminate any change caused by the circadian cycle.  
 The physical condition of the animals was monitored throughout the 
experiment. Special attention was given to the presence of stress signs, illness or poor 
physical condition, such as loss or gain of excessive weight, dehydration, aggressive 
social behavior, low mobility, bleeding and poor wound healing, infection of the 
sutures and opening of the stitches in the post-surgery period. 
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 The experimental procedures were performed according to ethical standards 
for the study of experimental pain in conscious animals [77], the Directive 2010/63/EU 
of the European Parliament and of the European Council [Strasbourg, 22 September 
2010] and the rules of the regulations of local authorities [Decree-Law 129/92, 
Ordinance 1005/92] on the use of animals for scientific purposes. 
 
Mice genotyping protocol 
 
For the DNA extraction, a fresh solution of 100mM NaOH was prepared and 
added to the microtubes containing the mice tissue. Samples were placed in the 
thermocycler at 99oC for about 1 hour. After cooling down, 100uL of 1M Tris HCl (pH 8) 
was added. After centrifugation, a 1 µL aliquot of the extracted DNA was used for the 
polymerase chain reaction (PCR). To each PCR tube was further added the following 
solutions from the Citomed BM-10002 KIT: 0.1 µL Taq polymerase, 2 µL of Buffer and 
2µL of MgSO4 (2 mM,). Finally, 1 µL of each primer (at 10 µM) was added, namely, 
primer 206: 5’-CTTGGGTGGAGAGGCTATTC-3’, primer 207: 5’-
CACAGCTGCGCAAGGAAC-3’, primer 208: 5’-GTAGCAACCCTCAGATGGAC-3’ and primer 
209: 5’-GAGGACTGGACCAAGGTTGT-3’, all produced by Stab Vida. 
The samples were placed in a thermocycler, which conducted 35 cycles of reaction. 
Each cycle included 5 minutes at 95oC, followed by 30 second at 95oC, 62oC and 72oC, 
and finally 10 minutes at 72oC. At last, the samples were run in an agarose gel for 
electrophoresis. The amplified target sequences included a mutated allele with 200 
base pairs (knock-out mice) and a wild-type allele with 100 base pairs (wild-type mice). 
When both products were found in the gel, the sample belonged to a heterozygous 
mouse, as we can see in the following gel-example (Figure 7).  
 
Figure 7 - Agarose gel. Het- heterozygote mice; WT- wild-type mice (100 base pairs); KO- knock-out mice (200 base 
pairs). 
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Visceral Pain: Writhing test induced by intraperitoneal acetic acid injection 
 
The acetic acid-induced visceral pain model is widely used in experimental 
research to produce a writhing reaction, characterized by contraction of the abdominal 
musculature and extension of the hind limbs (Figure 8), associated with visceral pain 
[24]. Animals were placed in the test chamber, a clear 20 × 26 × 12 cm plastic cage 
(figure 8), for 10 to 15 minutes to acclimatize. Following the intraperitoneal injection 
of 1% acetic acid (10ml/kg of body weight; Sigma-Aldrich, [24]), animals were placed 
back into the test chamber and were video-recorded for twenty minutes. Behavior was 
analyzed later with the program Etholog 2.25 [78]. The number of writhes was 
monitored for twenty minutes and recorded in five minutes intervals [24]. The total 
number of writhes between 5 and 15 min after injection [51, 79] and the latency time 
to the occurrence of the first writhe were also assessed. 
 
Figure 8 - Contraction of the abdominal musculature and extension of the hind limbs. 
 
Induction of Chronic Inflammatory Pain: Complete Freund’s Adjuvant Model 
 
The animals were anesthetized with volatile anesthesia (isoflurane), at first in a 
glass chamber at 4% (to induce) and then directly on the nose at 1.5% (to maintain). 
Then, animals received an intraplantar injection of 20 µL of Complete Freund’s 
adjuvant (CFA) into the left hind paw. The injection was performed slowly to avoid the 
reflux of CFA. The CFA solution consists of water in oil emulsion containing killed and 
dried Mycobacterium butyricum (Difco Laboratories [80]; see composition in annex). 
The inflammation reaction was monitored daily using a scale that takes into 
account the animal’s behavior and local inflammation signs. The inflammatory scale 
considered has the minimum value of zero, where the animal shows no signs of 
inflammation, and the maximum value of four, where the animal demonstrates severe 
inflammation and persistent flexion of the paw [81]. 
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 Mice were transferred to the behavioral testing room at least one hour before 
testing to acclimatize. The von Frey and Hargreaves behavioral tests (see below) were 
performed at three hours, one day and two days after injection. Both hind paws were 
tested.  
Induction of Chronic Neuropathic Pain: spared nerve injury (SNI) model 
 
The spared nerve injury surgery in mice was performed in order to induce a 
painful neuropathy, as described by Richner et al. [82] which is based on the procedure 
defined by Decostered and Woolf [19] in rats.  
Briefly, the animals were anesthetized using the combination of Domitor (1 
mg/kg, medetomidine hydrochloride) with Imalgene (75 mg/kg, Ketamine 
hydrochloride) diluted in distilled water and administered intraperitoneally. The left 
thigh was shaved and disinfected with Betadine and 70% ethanol. A 1 cm incision was 
made in the skin in the longitudinal direction proximal to the knee, subsequently 
detaching the skin from the underlying connective tissue layer covering the muscle. 
The muscle layer was separated with the help of blunt scissors, right next to the clearly 
visible blood vessel, close to the thigh bone (femur). At this point, a stereo microscope 
was required so the sciatic nerve and its different branches (tibial, peroneal and sural) 
could be visualized. A silk suture (6-0, No. 18020-60, Fine Science Tools) was applied 
around the tibial and peroneal branches, and a tight surgical knot was made, leaving 
the sural branch intact. Both nerves (tibial and peroneal) were held with a sterile 
tweezer bellow the suture and a 1 mm portion was cut with a small scissor. The muscle 
layer and the skin were sutured using absorbable 4-0 suture (simple knots in the 
muscle layer and U-eversion knots in the skin; C1048213, Safil, Braun) and lidocaine 
was applied to minimize local discomfort. After surgery, the wound was disinfected, 
the animals were rehydrated with a subcutaneous injection of 0.5 mL of saline solution 
(0.9 % NaCl) and finally, the anesthesia was reverted with a subcutaneous injection of 
Antisedan (atipamezol, 1 mg/Kg). In the days after surgery, easy access to water and 
food were provided. The von Frey, Acetone and the Hargreaves behavioral tests (by 
this order, see details of the tests below) were performed one day before surgery and 
on day one, three, seven and fourteen after surgery. The Cold Plate test was 
performed just on day 14 of SNI (see details below) after the other three tests. 
 
Acute pain behavioral tests   
 
These tests were applied to naïve mice and some were also used to assess the 
development of allodynia and hyperalgesia in chronic pain animals, as mentioned 
above. Acute pain tests were performed in naïve animals to detect differences in acute 
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sensitivities between both genotypes. The tail pressure and cold plate tests were 
performed in these animals to assess mechanical and cold hyperalgesia, respectively.  
To assess acute mechanical sensitivity and heat hyperalgesia in naïve animals, 
the von Frey and Hargreaves tests were performed, respectively, at the baseline time 
point of the CFA animals (before CFA injection), since at baseline all the animals were 
naïve. 
Von frey 
 Mechanical allodynia was assessed both in naïve and in chronic pain animals 
using a set of calibrated von Frey filaments (Figure 9B; Touch test sensory evaluator 
kit, Stoelting). Starting from the thinnest hair, each filament was applied on the plantar 
surface of the hind paw (Figure 9A) (for naïve and CFA-mice) or on the lateral area of 
the hind paw (innervated by the spared sural nerve for the SNI-mice) five consecutive 
times for thirty seconds until a response was observed. A response was considered 
positive if the mouse licked or removed the paw from the platform in response to the 
application of the filament. Both paws were tested. The threshold was considered as 
being the lowest filament force that provoked a paw withdrawal response (adjusted 
from [83]).  
 
 
Figure 9 - A) Von Frey test. B) Calibrated von Frey filaments. 
Tail Pressure  
 In naïve animals, mechanical hyperalgesia was assessed by only using the tail 
pressure test [84]. The animals were introduced in the metal restrainer, leaving the tail 
out and loose in order to place it on a small platform under the conic tip of the Randall 
Selitto apparatus (Figure 10) (Ugo Basile, Biological Research, Comerio). Pressing the 
apparatus pedal, an increasing force was applied to the animals’ distal tail portion 
(about 1-2 cm from tail tip), until the first pain response was observed. A response was 
considered positive if the mouse struggled, squeaked, or tried to remove the tail from 
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the platform. The force that elicited the noxious reaction was noted. In the absence of 
any reaction, a 250 g cut-off value was used to avoid tissue damage. The procedure 
was repeated, so that two measures were taken per animal. The nociceptive value 
(grams) for each mouse was taken as the mean value of two consistent measurements. 
 
 
Figure 10 - Randall Selitto apparatus. 
Cold plate  
This test was used to assess the sensitivity to noxious cold  (adapted from [85]). 
Naïve mice were placed on a 0 °C metallic plate, surrounded by an acrylic chamber 
(figure 11) (Hot/cold plate apparatus, Bioseb, France) so that the animals were 
restricted to move only on the plate area and their behavior was recorded for 120 
seconds. Two parameters were measured: the latency to hind paw flinching/flicking, 
licking, or jumping was measured at the time of testing by the device, and the number 
of times the animal flinched the hind paws during the 120 seconds period which was 
evaluated later by video analysis using the software Etholog 2.25 [78]. To evaluate 
thermal hyperalgesia in the 14 day SNI-mice, the plate was set to a temperature of 5 °C 
instead, and the evaluation of the latency of response was confined to the hind paw 
ipsilateral to the nerve lesion. The animals’ behavior was video-recorded for 300 
seconds for analysis of the total number of flinches with Etholog 2.25, as explained 
above.  
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Figure 11 - Cold plate test. 
Hargreaves 
 The mice were placed in the Hargreaves apparatus (Figure 12) (Plantar test # 
37370, Ugo Basile, Biological Research, Comerio), which was designed with the 
purpose of allowing the assessment of thermal allodynia and hyperalgesia in the paws 
(adapted from [86]). Using an infra-red setting of 50 units and a cut-off time of 15 
seconds to avoid tissue damage, three to four measurements were obtained for each 
hind paw. In naïve and CFA-mice, the laser beam was directed to the middle of the 
plantar region of the animal’s hind paw whereas in SNI-mice the hypersensitive lateral 
area of the paw was targeted. The latency of both paws was measured. For each 
mouse 3-4 readings were obtained during a period of 30 min (5-10 min interval) and 
the mean latency of 3 consistent measurements was used for analysis.  
 
Figure 12- Hargreaves test. 
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Acetone  
 The acetone test allows evaluating thermal allodynia, and was only performed 
in SNI-mice. A syringe with a piece of rubber tubing attached to its end was filled with 
acetone and the plunger depressed so that a small drop of acetone formed at the top 
of the tubing. The syringe was raised to the hind paw from below, depositing the 
acetone drop on the hypersensitive lateral-external part of the hind paw (Figure 13). 
The total duration of time of lifting, licking, flinching, shacking, and rotating of the 
torso was determined with the help of a chronometer. If necessary, the procedure was 
executed again 5 minutes later. If the animals did not respond to two measurements, it 
was assumed a minimum response value of 0.5 seconds, considered the normal 
response (adapted from [87]). 
 
Figure 13 - Acetone test. 
 
Perfusion, fixation and dissection of the biological material 
 
All the animals from the different pain models were perfused two hours after 
the beginning of the last acute behavioral test performed, when c-Fos expression is 
thought to achieve the peak. The animals were injected in the intraperitoneal cavity 
with diluted Eutasil® (67 mg/Kg sodium pentobarbital in 0.9% saline solution). In order 
to perfuse the mice, both abdominal and thoracic cavities where opened and the heart 
was exposed. An incision was performed in the left atrium with the help of a scissor to 
allow the blood to flow out. Afterwards, a needle was introduced into the left 
ventricle, allowing the washing solution (Tyrode’s pH 7.2) and the tissue fixative to 
circulate and leave the organism. The tissue fixative was a solution containing 4 % of 
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paraformaldehyde diluted in a phosphate buffer (pH 7.2). Naïve animals were perfused 
in a similar way. 
 At the end of the perfusion the animals’ tissues were carefully dissected. For 
naïve mice and animals from the chronic inflammatory pain and neuropathic pain 
models, the brain and the segments L3-L6 of the spinal cord as well as the associated 
L4 and L5 DRG were collected. For the animals from the visceral pain model, the 
segments T5 to L2 were collected, as well as the brain. The biological material was 
post-fixed for 4 hours, in paraformaldehyde 4% at 4oC, and then cryopreserved in 30 % 
sucrose with azide (to prevent microbial contamination) for, at least, 48 hours.  
 
Processing and sectioning of the biological material 
 
 The DRGs were separated from the spinal cord and kept in 30 % sucrose with 
azide until further use. A precise incision was performed in the contralateral side of the 
ventral horn of the spinal cord in relation to the affected paw, in the case of CFA and 
SNI-mice, to allow a clear distinction between both sides of the spinal cord and the 
identification of the ipsilateral dorsal horn. The spinal cord of the animals from the 
visceral pain remained intact, as it was not necessary to discriminate spinal cord sides 
in this case.  
 The spinal cords were frozen and transversely sectioned in four consecutive 
series of 30 µm thickness sections in the freezing microtome (Leitz, Barcelona). The 
obtained slices were transferred into a cryoprotector solution and preserved at -20oC 
for subsequent immunohistochemistry reactions.  
 The DRGs were sliced with a 10 µm thickness in the cryostat (Leica, Germany). 
They were collected in glass slides in three (L4) or four (L5) consecutive series. After 
thawing the sections on the glass slides at 37oC for 1h the slides were kept at-20oC for 
tissue preservation until subsequent immunohistochemistry processing.  
 
Immunohistochemistry reactions 
 
Anti-amylin in DRGs 
The immunohistochemistry reactions for detection of amylin expression in L4 
and L5 DRGs of naïve mice were performed on the glass slides. Two hours before the 
reaction, the slides were re-heated in a plate at 37 o C to defrost the tissue. The 
sections were washed with phosphate buffered saline (PBS) 0.1 M and with a solution 
of PBS with Triton-X100 (PBST), and were then blocked for 1 hour in a blocking solution 
containing 10% normal horse serum (NHS) in PBST. After blocking, the sections were 
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incubated overnight at room temperature in a PBST solution containing 2% of NHS and 
the polyclonal primary antibody against amylin made in rabbit (1:800 Bachem T-4146). 
Afterwards, sections were washed and incubated in the secondary antibody 
donkey anti-rabbit alexa-488 (1:1000; A21206, Molecular Probes) in PBST for 1 hour at 
room temperature. The sections were subsequently washed with PBST and PBS and 
finally were mounted using glycerol phosphate as mounting media. 
Anti CGRP in DRGs 
The immunohistochemistry reactions for detection of CGRP expression in L4 
and L5 DRGs of naïve mice were performed on the glass slides. Briefly, the 
immunohistochemistry reactions followed the same steps as the anti-amylin reactions, 
excepting the incubation in the primary and secondary antibodies. In this case, the 
sections were incubated in polyclonal primary antibody against CGRP made in sheep 
(1:1000 BML-CA1137, Enzo) and in the secondary antibody donkey anti-goat alexa-488 
(1:1000 A11055, Molecular Probes). 
Anti c-Fos in spinal cord 
C-Fos expression in the spinal cords was determined by an 
immunohistochemistry reaction in free-floating sections. This reaction was performed 
in segments L3 to L6 in the neuropathic model, since these are responsible for 
processing information from the hind paws. For the visceral pain model, the spinal 
cord segments T5 to L2 were used, as these receive the primary afferent fibers that 
transmit information relating to the internal peritoneal organs.  
 For the immunohistochemistry reaction, the spinal cord sections were 
transferred to cell culture plates and washed with PBS 0.1 M. In order to block the 
endogenous peroxidase activity, the tissue was incubated with a solution of 1% 
hydrogen peroxide (H2O2) in PBS for 15 minutes. After washing with a solution of PBST, 
the sections were incubated for 90 minutes at room temperature with a blocking 
solution containing 10% normal swine serum (NSS) in PBST to prevent antibody 
binding to nonspecific antigenic sites. Spinal cord sections were subsequently 
incubated with a polyclonal antibody anti-c-Fos made in rabbit (ABE457, 
MerkMillipore) at a dilution of 1:1000 in PBST with 2% NSS for 48 hours at 4 °C.  
Then, sections were incubated at room temperature with a secondary 
biotinylated IgG anti-rabbit (Dako, Glostrup) made in pig diluted in a ratio of 1:200 in 
PBST 2% NSS for 75 minutes. Following 1 hour incubation in an avidin-biotin-
peroxidase complex (ABC kit, Vectastain, Peterborough) solution, to amplify the signal 
four-fold, sections were equilibrated in a 0.05 M Tris-HCl pH 7.6 solution before the 
reaction with 3,3-diaminobenzidine (DAB; Sigma Aldrich) diluted in the same buffer 
containing 0.025% H2O2. The oxidation of the DAB due to the peroxidase action 
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produced a brown precipitate in the antigen-antibody reaction sites. The reaction was 
then stopped by washing the tissue with Tris-HCl 0.05M pH 7.6 solution again. All steps 
were performed under moderate agitation. After the immunohistochemistry reaction, 
sections were placed in gelatin-coated slides and left at 37 °C overnight to dry. The 
next day, they were cleared in xylene (Prolabo Carnaxide) for 1 minute, covered with 
mounting medium (Entellan; Merk, Germany) and cover-slipped. 
 
Histological Hematoxylin-Eosin staining 
 
In order to quantify the number of L4 and L5 DRG neurons from naïve WT and 
amylin KO mice and measure their cell body areas, an histological staining with 
hematoxylin and eosin (H&E) was performed to label all the cell bodies in the DRG 
sections.  
Briefly, the DRG slices were hydrated with tap water. Then, the slices were 
dipped in hematoxylin solution for about 90 seconds. Sections were then washed with 
water again before counter-staining with eosin for about 30 seconds. The slices were 
washed again and then dehydrated sequentially in a 90% ethanol solution and then 
absolute ethanol. Sections were then cleared in xylol and mounted with Entellan.  
 
Quantification of c-Fos-positive neurons in the spinal cord 
 
The sections immunoreacted against c-Fos were analyzed using an optical 
microscope (Leica) coupled to a digital camera (Leica camera) and specific computer 
image software (LAS 4.6- Leica Application Suite). Per SNI-animal, 8-10 slices from 
segments L3 to L6 were chosen and for visceral pain animals, 10-12 sections from T5 to 
L2 region of the spinal cord were selected for analysis. The selected slices were 
photographed and then the c-Fos positive nuclei were counted in the captured images 
by using Image J software version 1.37 (free access software). 
The central canal was used as a marker to divide the spinal cord into its dorsal 
and ventral parts. The nuclei positive for c-Fos were quantified only in the dorsal horn 
ipsilateral to the paw subject to the SNI surgery in the animals from the neuropathic 
pain model (Figure 14 A). The expression of c-Fos in the spinal cord sections from the 
animals of the visceral pain model was quantified in both dorsal horns (Figure 14B). 
FEUP 
Amylin’s role in nociception: study in amylin KO mice 
 
48 
  
 
Figure 14 - Illustration of the spinal cord region considered for quantification of c-Fos. A) considered area for the 
neuropathic pain model. B) considered area for the visceral pain model. 
The average of the number of cells positive for c-Fos in each analyzed area was 
used for statistical analysis. 
 
Quantification of CGRP-positive neurons and determination of neuronal cell 
body areas in DRGs of WT and KO mice  
 
 Immunohistochemistry analysis of L4 and L5 DRGs was performed using a 
fluorescence microscope (AxioImager Z1; Zeiss) coupled to a digital camera (AxioCam 
MRm) and computer image software (AxioVision 4.6) to capture the images.  
 The total number of neurons, as well as the number of CGRP-positive neurons, 
per section, was counted using ImageJ software. This allowed calculating the 
percentage of CGRP-positive neurons. 
The neuronal cell body areas of CGRP positive cells and neurons from the L4 
and L5 DRGs from naïve animals were measured, in order to evaluate possible changes 
in the CGRP-positive neuronal population and in the global neuronal population in the 
two different groups of animals (WT vs. KO). Neurons were manually outlined in the 
captured images in the computer and the area was measured using the Image J 
program version 1.37 (free access software). Cell areas were grouped into three 
categories: small (<600 µm2), medium (600-1200 µm2) and large area neurons (>1200 
µm2) according to Negri et al [88]. 
 
Statistical Analysis  
 
Statistical analysis was performed using Prism software (version 5, GraphPad, 
California). The results were presented as mean ± standard error of mean (SEM) for 
each experimental group. The analysis of data normality was assessed by the 
Kolmogorov-Smirnov test and, whenever any of the experimental groups did not 
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present the expected Gaussian curve, the appropriate non-parametric tests were 
performed. If the data followed a Gaussian curve, parametric tests were done. The 
Grubb’s test was also performed in order to detect outliers when a result seemed to 
diverge substantially from the rest of the group. Data from the cold plate and tail 
pressure tests were analyzed by the Student’s unpaired t test to compare the two 
groups in the study. The nonparametric Kruskal-Wallis test was used to test the 
differences at each time point between experimental groups on data from the von 
Frey test, as the results appear in a logarithmic scale (force exerted by von Frey 
filaments).  
For data relative to the acetone, the Hargreaves and the Writhing tests 
throughout time, two-way analysis of variance (Two-way ANOVA) was used with 
repeated measures (time as repeated measure, in minutes or days) followed by the 
post-hoc Bonferroni test for the analysis of punctual differences.  
The percentage of CGRP-positive neurons in the DRGs and the different area 
distributions, in both hematoxylin-eosin stained and CGRP immunoreacted sections, 
was statistically analyzed by the Student’s unpaired t test. This test was also used to 
analyze data regarding the quantification of c-Fos expression in the spinal cords.  
In all statistical analysis p values < 0.05 were considered as significant. 
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Results and Discussion 
  
Acute pain tests 
 
Acute tests performed on naïve animals  
 Naïve animals, both knock-out for the amylin gene and wild-type animals were 
tested on acute pain behavioral tests in order to understand amylin’s role in acute 
nociceptive transmission.  
 The von Frey test was conducted in order to assess differences in mechanical 
allodynia between WT and amylin KO mice (Figure 15). WT animals responded to 
filaments which induced forces around 0.27±0.09 g, while KO mice responded to 
filaments which induce lower forces, in the average of 0.12±0.05g. However, the Mann 
Whitney test performed did not detect a statistical significant difference between both 
groups. The values observed in WT mice are consistent with those obtained in previous 
studies in mice ([89]), where wild-type mice showed a threshold of 0.29±0.04g.  
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Figure 15 - von Frey test in the plantar surface of KO and WT naïve mice hind paws. WT n = 5, KO n = 6. 
The tail pressure test was performed to assess mechanical hyperalgesia. As we 
can observe in Figure 16, amylin KO animals responded to significantly lower forces 
(7.73±0.84g) when comparing to WT animals which showed responses to average 
forces of 10.88±0.62g (p<0.05). The results from both mechanical tests are in 
agreement and suggest that, in normal conditions, amylin KO mice are generally more 
sensitive to mechanical stimuli than WT mice. 
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Figure 16 - Tail Pressure test in KO (n = 8) and WT (n = 6) naïve mice; *p<0.05 
 The Hargreaves test was also performed in these animals to assess thermal 
hyperalgesia. There were no significant differences between the two animal groups 
which suggest that amylin KO mice do not have altered sensitivities to noxious heat 
(Figure 17). Even though this would suggest that amylin is not involved in the 
mediation of noxious heat stimuli, there are previous studies showing an 
antinociceptive effect upon intracerebroventricular amylin administration in the hot 
plate test [63], which highlight a central modulatory role. 
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Figure 17 - Hargreaves test in WT (n=6) and KO naive mice (n=6). Paw withdrawal latency (PWL) of WT and KO mice 
hind paw. 
 The cold plate test was performed to determine cold hyperalgesia. The paw 
withdrawal latency was measured in both KO and WT naïve animals. When analyzing 
the results obtained, we observed that one of the animals exhibited an abnormal 
response that differed significantly from the other animals of the group. The Grubbs' 
test confirmed that this value was a significant outlier in the group (Figure 18) and thus 
this value was not considered for further statistical analysis. 
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Figure 18 - Grubb's test result for the data regarding the cold plate test in KO and WT naïve mice. 
The results of the cold plate test are represented in Figure 19). As can be 
observed, amylin KO animals elevated the hind paw lesser times than WT animals 
(18.33±2.911 flinches in WT versus 15.00±2.99 flinches in KO mice; Figure 19A), 
although the differences were not statistically significant. Furthermore, KO animals 
elevated the hind paw significantly later than the WT animals (PWL of 13.00±1.15 
seconds in WT versus 19.22±0.96 seconds in KO mice; p<0.05; Figure 19B) in response 
to the cold stimulus. Though the first result is not significant, it is in agreement with 
the second result, both suggesting that KO animals tolerate better the noxious cold 
than WT animals. 
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Figure 19 - Cold plate test in KO (n=10) and WT naïve mice (n=9). A) number of flinches; B) paw withdrawal latency. 
***p<0.05 
 It is interesting to note the dissimilarities in results when analyzing both 
thermal acute and mechanical acute pain tests. It is possible that the ionic channels 
working as detectors of cold stimuli are altered in KO mice, since they respond to 
noxious cold in a different manner compared to WT animals. The channels responding 
to cold include transient receptor potential melastatin 8 (TRPM8) [26], and are 
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expressed by A and C fibers [90], [84] that mediate cold stimuli and can be 
differentially expressed by these nociceptors. On the other hand, the ionic channel 
responsible for sensitivity to noxious heat is transient receptor potential vanilloid 1 
channel (TRPV1) and is almost exclusively expressed in C peptidergic nociceptors ([90], 
[84]). It is possible that the expression of these channels remains intact in KO mice, 
since they respond to heat practically the same way as WT animals. Taken these 
results together, it is reasonable to hypothesize that the expression patterns of TRPM8 
and/or that the A fibers on amylin KO mice may be altered. 
Inflammatory pain model  
The induction of inflammatory pain by CFA injection in the plantar paw elicited 
a strong immune response that resulted in a localized arthritic reaction. Indeed, both 
WT and KO mice developed a severe inflammation within the first three hours after 
injection, associated with adaptive postural changes, namely with persistent flexion of 
the paw, confirming the induction of the inflammatory pain model. This was reflected 
in an increased inflammatory score which reached values of 3.33±0.27 at 3 hours and 
remained significantly high until 2 days after CFA injection (Figure 20). The associated 
inflammation induced-nociceptive behavioral changes, which included mechanical 
allodynia and thermal hyperalgesia, were observed in both animal groups. As it was 
expected, the contralateral hind paw remained uninflamed in both genotypes. The lack 
of differences in paw inflammation between genotypes was expected, as it was 
already observed by Gebre-Medhin and colleagues that amylin KO mice had similar 
ankle joint diameters at different time points after intra-plantar CFA-injection, as WT 
mice [2].  
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Figure 20 - Evolution of inflammation in WT-CFA (n=6) and KO-CFA (n=6) animals. #p<0.001- WT and KO ipsilateral 
hind paws vs. WT and KO contralateral hind paws. 
In the von Frey test, the mean forces that provoked a noxious response in the 
WT animal group before inflammation induction (day 0) were of 0.27±0.09g. On the 
other hand, amylin KO animals generally responded to filaments exerting lower forces, 
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which were around 0.19±0.08g. Despite this tendency for the amylin KO animals to be 
more sensitive to mechanical forces, there were no significant differences between the 
two groups, at day 0 (p>0.05; Figure 21).  
 From three hours after injection until the end of the behavioral tests, we 
observed that the forces required to induce the contralateral hind paw withdrawal did 
not vary much, as expected, although we could note a slight increase in the KO animal 
group to values that were similar to the WT group (Figure 21). 
 As predicted, all animals showed a decrease in the forces required to induce 
ipsilateral hind paw withdrawal after CFA injection in comparison to the contralateral 
hind paws (Figure 21), confirming the development of mechanical allodynia. Even 
though there were no significant differences regarding the forces supported by the 
ipsilateral hind paws between WT and KO mice, we could observe that KO animals 
tended to respond to greater filament forces, at 3h and 2 days of inflammation, 
indicating that KO animals may have a tendency to develop less mechanical allodynia 
in inflammatory pain conditions. However, this was just a trend, without statistical 
significant alterations in the way the two animals groups answer to the mechanical 
stimuli.  
 The Kruskal Wallis test at each time point demonstrated only a significant 
difference between the WT ipsilateral hind paw and the KO contralateral hind paw 
(0.038±0.03g and 0.26±0.05g, respectively, p<0.05, Figure 21). The lack of significance 
when comparing to its own control (WT contralateral paw) is probably due to the large 
variability found within the groups, and to the relatively low number of animals tested. 
Thus, the ipsilateral hind paws from amylin KO animals tended to respond to similar 
forces when compared to both WT and KO non-damaged hind paws, contrarily to what 
happens to the ipsilateral hind paws of WT animals, which responded to lower force 
filaments.  
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Figure 21 - Mechanical allodynia evolution in WT (n=5) and KO mice (n=6) after CFA injection. *p<0.05- WT 
ipsilateral hind paw vs. KO contralateral hind paw, after 2 days of CFA injection. 
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 Our group found that chronic amylin administration promoted analgesia in rats 
that received intra-articular CFA injection (monoarthritic rats). Specifically, there was 
an attenuation of mechanical allodynia and hyperalgesia on days 7 and 13 of 
inflammation [76]. The abovementioned tendencies found in the von Frey test in mice 
lacking amylin are difficult to reconcile with the antinociceptive effects found upon 
chronic amylin administration in monoarthritic rats [76]. Still, one has to keep in mind 
that amylin KO mice do not express amylin constitutively, that is, since the embryonic 
phases of development. Therefore, the effects observed in amylin KO mice are not 
only a consequence of a temporary amylin lack, as a neuropeptide modulating pain, 
but rather the outcome of its permanent lack which may have affected the nociceptive 
system development, as further discussed later. 
Mulder and colleagues found an increase in amylin’s expression in rat L5-DRG 
at early time points of paw inflammation [91]. One could hypothesize that the small 
trends found in the responses in the von Frey test could be associated with the fact 
that amylin KO mice cannot overexpress amylin in response to inflammation. 
In order to assess thermal hyperalgesia in the chronically inflamed animals, the 
Hargreaves tests were performed. The hind paw withdrawal latency (PWL) to the hot 
beam was measured for both hind paws of both animal groups. The 2 way ANOVA 
statistical analysis performed along time showed that both animal groups presented a 
similar PWL around 9-10 seconds in both hind paws, (10.35±1.58s for the ipsilateral 
and 9.48±1.22s for the contralateral hind paws in WT mice; 9.60±1.32s for the 
ipsilateral and 10.30±1.16s for the contralateral hind paws in KO mice), at day 0 
(baseline), as expected (Figure 22).  
 In the non-damaged hind paw (contralateral), we did not detect any difference 
over time in any of the genotypes. As it was expected, the PWL in the ipsilateral hind 
paws decreased significantly at 3 hours after CFA injection in both animal groups 
(3.14±1.08s for the WT and 2.97±1.22s for the KO groups) (p<0.05), confirming that 
the model was well induced. At this time point, there were no differences between the 
two different genotypes comparing both ipsilateral hind paws, and the same happened 
at 1 and 2 days after CFA injection, which suggests that amylin plays no role in the 
response to noxious heat in inflammatory pain conditions. There were significant 
differences in the PWL values between the ipsilateral hind paws and the WT 
contralateral hind paw group on day 1 of inflammation (WT ipsilateral, p<0.01; KO 
ipsilateral, p<0.05: Figure 22), confirming that mice from both genotypes exhibited 
thermal hyperalgesia. However, we could note a slight tendency for KO animals to 
progressively increase their PWLs over time, since on day two, the ipsilateral hind paws 
of WT animals showed significantly lower PWLs comparing to KO contralateral paws. 
At this time, it was detected a tendency for the KO animals to exhibit higher PWLs in 
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their ipsilateral hind paws, which suggests that, at later stages of inflammation, KO 
animals might be less hypersensitive to thermal stimuli.  
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Figure 22 - Thermal hyperalgesia and allodynia evolution for KO (n=6) and WT (n=6) animals after CFA injection. # 
p<0,01 WT and KO ipsilateral hind paw vs. WT and KO contralateral hind paw, at 3 hours after CFA injection. 
**p<0.01 WT ipsilateral hind paw vs WT contralateral hind paw, one day after CFA injection. *p<0.05- KO ipsilateral 
hind paw vs. WT contralateral hind paw, one day after CFA injection. *p<0.05-WT ipsilateral hind paw vs. KO 
contralateral hind paw, 2 days after CFA injection.  
 Overall, the KO mice seemed to develop less allodynia and hyperalgesia upon 
this chronic inflammatory condition but significant differences between genotypes 
were not detected. However, as WT ipsilateral hind paws presented significant 
differences to non-damaged hind paws, contrarily to KO ipsilateral hind paws, this 
could indicate that WT mice were, in general, more responsive to the noxious stimuli 
applied. Due to technical problems, it was not possible to process the biological tissue 
of these mice, so it was not possible to support these results with the 
immunohistochemical analysis of c-Fos expression in the spinal cord.  
The differences between genotypes could become more evident with a higher 
number of animals per experimental group, which would allow developing more solid 
conclusions regarding the role of amylin in inflammatory pain.  
Pathological Pain Models: Neuropathic Pain  
The induction of neuropathic pain by using the spared nerve injury model 
resulted in long-lasting and intense allodynia and hyperalgesia in the lateral surface of 
the hind paw receiving innervation from the injured nerve. The nociceptive responses 
of both hind paws were evaluated on day -1 (baseline), and days 1, 3, 7 and 14 after 
SNI surgery by the von Frey, acetone, Hargreaves and cold plate tests.  
 In the von Frey test, both animal groups responded to similar filament forces at 
day -1 (0.33±0.10g for the ipsilateral and 0.38±0.12g for the contralateral hind paws in 
WT mice; 0.36±0.04g for the ipsilateral and 0.4±0.00g for the contralateral hind paws 
in KO mice; Figure 23). As it was expected, the force required to elicit a response 
significantly decreased from day one after surgery in the ipsilateral hind paws of both 
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animal groups (Figure 23), confirming the occurrence of mechanical allodynia. 
However, WT animals responded to statistically significant lower forces when their 
ipsilateral paws were stimulated, as compared to data from the contralateral hind 
paws of both groups (p<0.05), while KO animals did not (ipsilateral KO vs. contralateral 
WT or KO, p>0.05 for days 1 and 3).  
 At days 1 and 3, it became very evident that KO mice displayed less allodynia to 
mechanical stimuli (0.04±0.01g for the ipsilateral hind paw and 0.28±0.05g for the 
contralateral hind paw at day one and 0.05±0.02g for the ipsilateral hind paw and 
0.34±0.05g for the contralateral hind paw at day 3), unlike WT mice which presented 
significant differences from their internal controls (non-injured contralateral hind 
paws) (0.008±0.00g for the ipsilateral hind paw and 0.25±0.08g for the contralateral 
hind paw at day one and at day 3).  
However, at day 7 and 14 after surgery, the affected hind paws of both animal 
groups exhibited significant differences in von Frey test responses (0.008±0.00g for the 
WT mice and 0.02±0.005g for KO mice) comparing to the contralateral hind paws of KO 
animals (which responded to mean values of 0.22±0.05g). Although the KO ipsilateral 
hind paws also showed a significant difference in response comparing to the 
contralateral hind paws response of KO mice, these differences were significantly 
smaller (p<0.05; Figure 23) than those presented by WT animals (p<0.01; Figure 23). 
Data obtained for WT animals are in agreement with results previously described, 
before and after SNI surgery in mice [92].  
 Even though there were no significant differences in the response when 
comparing the hind paws in the same condition between both genotypes (WT 
ipsilateral vs. KO ipsilateral and WT contralateral vs. KO contralateral), it was detected 
a tendency for KO animals to elicit a noxious response only when higher force 
filaments were applied.  
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Figure 23 - Mechanical allodynia progression for WT and KO mice after SNI surgery. *p<0.05- WT ipsilateral hind 
paw vs. WT contralateral hind paw, at day 1 after SNI surgery. **p<0.05-WT ipsilateral hind paw vs. KO 
contralateral hind paw, at day 1 after SNI surgery. ** p<0.05-WT ipsilateral hind paw vs. KO contralateral hind paw, 
at day 3 after SNI surgery. ** p<0.05-WT ipsilateral hind paw vs. KO contralateral hind paw, at day 7 after SNI 
surgery. * p<0.05- KO ipsilateral hind paw vs. KO contralateral hind paw, at 7 days after surgery. ** p<0.05-WT 
ipsilateral hind paw vs. KO contralateral hind paw, at day 14 after SNI surgery. * p<0.05- KO ipsilateral hind paw vs. 
KO contralateral hind paw, at 14 days after surgery. (WT n=4; KO n=6) 
 With the purpose of assessing cold allodynia, the acetone test was performed 
on day -1, 1, 3, 7 and 14 of SNI. As depicted in Figure 24, all animals responded 
similarly before surgery (no response or fast hind paw removal considered as a 0.5 
seconds time of response), indicating that cold allodynia was not present before the 
surgery and neuropathic pain development.  
 Unsurprisingly, one day after surgery, the injured hind paws of both animals 
(KO and WT) responded (lifted their paws) for a longer time to the acetone drop when 
compared with the corresponding uninjured hind paws (contralateral hind paw of WT 
and KO mice responded for 1.12±0.31s and 0.91±0.23s, respectively and ipsilateral 
hind paw responded for 3.50±1.04s in WT mice and for 2.66±0.61s in KO mice), 
confirming the development of cold allodynia. Though, only WT animals showed 
significant differences in their responses, comparing to the contralateral hind paw of 
KO animals (p<0.05, Figure 24). This significant response was also observed on day 7 
after surgery.  
 On day 1 and 3 of SNI, there was a tendency for KO animals to have shorter 
duration responses, though there were no significant differences between genotypes, 
suggesting a tendency for KO mice to be more insensitive to cold stimuli. This is in 
agreement with previous results from our group indicating that chronic amylin 
administration aggravates cold allodynia in SNI-rats [75]. 
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Figure 24 - Assessment of cold allodynia by the acetone test, after SNI surgery in WT and KO mice. *p<0.05-WT 
ipsilateral hind paw vs. KO contralateral hind paw, at day 1 after SNI surgery. **p<0.01 WT ipsilateral hind paw vs. 
KO contralateral hind paw, 7 days after SNI surgery. (WT n=4; KO n=6) 
 
In the Hargreaves test, in which thermal hyperalgesia and allodynia were 
assessed, no significant differences were observed throughout most of the 
experimental period, except on day 7 after surgery, when WT animals exhibited a 
significantly lower PWL in their ipsilateral hind paw (4.58±0.46s), when comparing to 
both WT and KO contralateral hind paws (9.55±1.27s and 8.87±0.72s, respectively; 
p<0.05; Figure 25). At this time point of neuropathy, the ipsilateral PWL of KO animals 
did not show significant differences in comparison to all groups.  
As expected, the PWL of ipsilateral hind paws of both groups of animals were 
lower than the values obtained in the contralateral control hind paws (Figure 25), 
which is a consequence of the SNI surgery.  
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Figure 25 - Thermal hyperalgesia and allodynia evolution in SNI pain model animals. *p<0.05- WT ipsilateral hind 
paw vs. WT contralateral hind paw, 7 days after SNI surgery. *p<0.05- WT ipsilateral hind paw vs. KO contralateral 
hind paw, 7 days after SNI surgery. (WT n=4; KO n=6) 
As aforementioned, the cold plate test was performed only at 14 days after 
surgery in order to assess cold hyperalgesia. The number of hind paw flinches was 
counted and the ipsilateral hind paw withdrawal latency was measured. As observed in 
Figure 26, the slight differences between the two genotypes were not statistically 
significant. There was a tendency for KO animals to flinch less often the affected hind 
paw (19.00±7.88 and 13.17±2.05 for WT and KO mice, respectively, Figure 26A) and to 
withdraw the same hind paw later in response to the stimulus (24.83±3.23 and 
34.65±4.17 for WT and KO mice, respectively, Figure 26B). Both results are in 
accordance with each other, suggesting that KO SNI-animals tended to show greater 
tolerance to noxious cold than WT SNI-mice 
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Figure 26 - Cold Plate tests on KO (n=6) and WT (n=4) mice, 14 days after SNI pain model induction. A) number of 
ipsilateral hind paw flinches; B) ipsilateral hind paw withdrawal latency (PWL). 
 Taken together, these results suggest that the KO SNI-mice are less sensitive to 
the different applied stimuli, showing less signs of neuropathic pain. These results 
were supported by the expression of c-Fos, an immediate early gene that is rapidly and 
specifically expressed by spinal cord neurons in response to noxious stimulation [38]. 
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Indeed,  WT mice showed a significantly higher number of c-Fos positive neurons than 
KO mice (68.91±3.33 and 53.09±3.17 for WT and KO mice, respectively; p<0.05, Figure 
27), suggesting that more spinal cord nociceptive-responsive neurons were activated 
in WT SNI-mice, which supports the results obtained in the behavioral tests. Thus, we 
can conclude that amylin KO mice displayed less pain-associated behaviors after SNI 
surgery than the WT animal group, suggesting that, in WT animals, amylin may play a 
role in the mechanisms leading to chronic pain settlement after peripheral nerve injury 
by promoting the development of allodynia and hyperalgesia.  
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Figure 27 - A) c-Fos quantification on the ipsilateral side of WT and KO animals’ spinal cords, after 14 days of SNI 
surgery. *p<0.05- WT mice vs. KO mice; B) Schematic drawing of the L4 segment of the spinal cord (from [33]) 
representing the dorsal horn area used for c-Fos quantification; Microphotographs showing the c-Fos expression in 
ipsilateral site of L4 spinal cord slices. C) c-Fos immunohistochemistry in WT animal spinal cord; D) c-Fos 
immunohistochemistry in a KO animal spinal cord. WT n=4; KO n=5. 
Visceral pain model: The writhing test  
After intraperitoneal injection of acetic acid, mice were placed in a plastic 
chamber and their behavior was video recorded for 20 minutes. Hyperalgesia was 
measured by counting the number of writhes in 5 minute time-periods for 20 minutes 
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(Figure 28A) and the total number of contractions between 5 and 15 minutes post-
injection (Figure 28B), when pain behavior is usually maximal [24, 79].  
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Figure 28 - Writhing test in WT e KO mice after acetic acid injection. A) Number of writhes over 20 minutes. B) Total 
number of writhes after intraperitoneal injection of acetic acid, from 5 minutes after acetic acid injection to 15 
minutes after acetic acid injection.* p<0.05- WT mice vs. KO mice. WT n=7; KO n=7. 
 As can be observed in Figure 28A, though there were no significant punctual 
differences between the two animal groups, there was a time effect, as KO and WT 
animals diverge over time (Figure 28A) with a tendency for amylin KO mice to display 
more writhes per 5 minutes at the later time points of the test (15 and 20 min). 
Accordingly, KO animals had in total significantly more writhes than WT animals, 
between minute 5 and minute 15 (29.00±3.57 and 42.29±4.76 for WT and KO mice, 
respectively; p<0.05, Figure 28B). Although there were no statistically significant 
differences for the number of writhes in 5 minute time-periods between genotypes 
(Figure 28A), this data is in agreement with data in Figure 28B, and altogether they 
suggest an anti-nociceptive role of amylin in visceral pain as amylin KO mice injected 
with acetic acid displayed more pain-related behaviors. 
 Moreover, the analysis of c-Fos expression after the writhing tests showed that 
KO mice expressed significantly more c-Fos than WT mice (Figure 29). This result is in 
agreement with the behavioral analysis, as more c-Fos expression is usually associated 
with more pain. These results comply with data from Huang et al (2000) that proposed 
an anti-nociceptive role of amylin as both intraperitoneal and intrathecal amylin 
administration attenuated the number of writhes in the same visceral pain model.  
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Figure 29 - A) c-Fos quantification on WT and KO animals’ spinal cords, after acetic acid injection. *p<0.05 B) 
Schematic drawing of the T13 segment of the spinal cord (from [33]) representing the dorsal horn area used for c-
Fos quantification; Microphotographs showing the c-Fos expression in the dorsal horn of T13 spinal cord slices: C) c-
Fos immunohistochemistry in WT animal spinal cord; D) c-Fos immunohistochemistry in KO animal spinal cord. WT 
n=6; KO n=6.  
 
Quantification of neuronal density and cell body area of DRG neurons 
 
The hematoxylin and eosin (H&E) staining was performed to label all the cells in 
L4 and L5 DRG in naïve mice (Figure 30). This allowed inferring the neuronal density 
(Figure 30A) in the DRGs of both WT and KO mice groups, as well as the neuronal cell 
body areas and their categorization per size (Figure 30B).  
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Figure 30 - Neuronal density and cell body area in L4 and L5 DRGs from WT (n=4) and KO (n=5) naïve mice. A) 
Neuronal density in WT and KO naïve animals. B) Cell body areas distribution in WT and KO naïve mice. *p<0.05- cell 
body area>1200 WT vs. cell body area>1200 KO. C) Hematoxylin and eosin staining in a L5 DRG slice of WT mice. D) 
Hematoxylin and eosin staining in a L5 DRG section of KO mice 
 As observed in Figure 30A, there were no significant variations on the neuronal 
density, when comparing WT and KO animals. Still, KO animals showed a slight 
increase in the number of neurons per area, although this was not significant, probably 
due to the low number of animals analyzed. This small trend can be explained by data 
regarding the average neuronal cell body area shown in Figure 30B). As shown, KO 
animals tended to have more small-sized neurons (<600 µm2; 82.21±1.17 and 
86.48±1.24 for WT and KO mice, respectively; p=0.08) and had significantly less large-
sized neurons (>1200 µm2), comparing to WT animals (0.82±0.16 and 0.32±0.10 for WT 
and KO mice, respectively; p<0.05).  
In summary, in amylin KO mice, the large-sized neurons, known as Aβ, are 
scarce, while the small-sized neurons, presumably C and Aδ fibers, are in tendency 
more abundant. It has been reported that, in amylin KO mice, the number of neuronal 
cell bodies in DRGs was depleted until around birth [93]. Authors suggested a 
transitory role for amylin as a growth factor or a neurotrophic action in a subgroup of 
neurons that were replaced by other neuronal populations in the DRGs around birth. 
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The behavioral and histological results reported in this thesis support the latter 
possibility, in which amylin’s lack leads to a misrepresentation of large-sized neurons 
and a compensatory tendency to a greater proportion of small-sized neurons in the 
DRGs. These small-sized neurons transmit noxious stimuli, which may in part explain 
the increased sensitivity observed by naïve amylin KO mice in acute mechanical pain 
tests.  
The range of neuronal cell body areas obtained was similar to those previously 
described by similar studies [88, 94].  
 
Immunohistochemistry results 
 
Amylin immunolabeling  
 In order to confirm that KO animals did not express amylin in the nervous 
system, as expected since these animals have a generic ablation of the amylin gene in 
all body tissues, we performed an immunohistochemistry reaction for the detection of 
amylin’s expression in the DRGs of both WT and KO mice groups (Figure 31). As shown, 
no amylin expression was found in KO mice DRG neurons, contrarily to WT mice in 
which many amylin-positive neurons could be observed. 
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Figure 31 - Fluorescence microphotographs of Immunohistochemistry reaction amylin (green) in lumbar 4 DRG of WT 
naïve mice (A) and KO naïve mice (B). 
Quantification of CGRP expression 
 The percentage of neurons that expressed CGRP was quantified, as well as the 
areas of the same neurons, in order to assess whether behavioral changes in KO mice 
were caused by alterations in the number of C-peptidergic nociceptors or if CGRP 
would be expressed in amylin KO animals in a neuronal population with a size different 
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than what is normally observed in WT animals. As shown in Figure 32, there were no 
significant differences between WT and KO mice in the percentage of neurons which 
expressed CGRP in L4 and L5 DRGs (12.80±1.43 and 10.43±1.06 for WT and KO mice, 
respectively).  
CGRP % from total neurons
L4-5 DRGs
WT KO
0
5
10
15
20
%
 C
G
R
P
 n
e
u
ro
n
s
 
A 
 
C 
% CGRP
L4-5 DRGs
<600 600-1200 >1200
0
20
40
60
80
Cell body area (m2)
%
 n
e
u
ro
n
s
 
B 
 
 
D 
Figure 32 - Results from CGRP immunohistochemistry in lumbar 4 and 5 DRGs of WT (n=5) and KO (n=5) mice. A) 
Percentage of CGRP-positive neurons in L4 and L5 DRGs of WT and KO naive mice. B) cell area distribution of CGRP-
positive neurons from L4 and L5 DRGs of WT and KO naive mice. Fluorescence microphotographs of lumbar 5 DRG in 
C) WT mice DRG after CGRP immunohistochemistry reaction. D) KO mice DRG after CGRP immunohistochemistry 
reaction 
Additionally, KO animals have a tendency to have more medium-sized CGRP-
positive neurons than WT mice (25.38±1.72 and 29.91±3.09 for WT and KO mice, 
respectively; Figure 32B). However, there were no significant differences on the area 
distribution of neurons expressing CGRP. Both animal groups had no CGRP-positive 
large-sized neurons, as expected.  
Overall, we can say that KO mice did not reveal significant alterations in their C-
peptidergic population of DRG neurons, proposing that the fibers which are related to 
the behavioral alterations in pain thresholds may be related to either C-non-
peptidergic fibers or Aδ fibers. Still, this later possibility needs further study. 
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In summary, it is possible that the variations in KO mice pain behavior are not 
related with changes in C peptidergic fibers but may be caused by a phenotypic switch 
between neuronal types from Aβ to Aδ fibers, as amylin KO mice showed reduced 
numbers of large area neurons in the DRGs.    
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Conclusions and future perspectives  
 
According to the acquired data, amylin’s role in nociception seems to diverge 
depending on the pain model induced and on the nature of the noxious stimulus. In 
naïve mice, the results from both mechanical tests are in agreement and suggest that, 
in normal/basal conditions, amylin KO mice are generally more sensitive to mechanical 
stimuli than WT mice. Here, amylin displays a putative role as a neuropeptide 
promoting anti-nociception. Contrarily, when cold hyperalgesia was assessed by the 
cold plate test, amylin’s role seemed to be pro-nociceptive, since WT animals were 
more sensitive to thermal stimulus. On the other hand, the Hargreaves test showed no 
significant differences between the two animals groups. These dissimilarities observed 
between the results of the two thermal types of stimuli lead us to believe that the 
channels which function as detectors of cold stimuli are altered in KO mice, since they 
respond to noxious cold in a different manner compared to WT animals. These 
channels, TRPM8, are expressed by A and C fibers. We hypothesize that the expression 
patterns of TRPM8 and/or that the A fibers on amylin KO mice may be altered. We 
considered no changes in C fibers, since they express the channels which function as 
detectors of heat stimulus (TRPV1), and we did not notice behavioral changes when 
heat stimuli were applied to both animal groups (WT and KO). Furthermore, there 
were no significant changes in the proportion of the CGRP neuronal population in the 
KO animals DRGs. 
In the inflammatory pain model, induced by CFA, KO mice had higher response 
thresholds but significant differences between genotypes were not detected. 
However, as WT ipsilateral hind paws present significant differences comparing with 
the non-inflamed hind paws (WT and KO contralateral hind paws), contrarily to KO 
ipsilateral hind paws, we could conclude that WT mice were generally more responsive 
to the noxious stimuli applied, suggesting a pro-nociceptive role of amylin in this 
inflammatory pain model. The differences between genotypes could become more 
evident if we had increased the number of animals per experimental group, which 
would allow developing more solid conclusions on this pain model.  
In the neuropathic pain model, induced by the spared nerve injury surgery, we 
could observe that amylin KO mice displayed less pain-associated behaviors after SNI 
surgery than the WT animal group, suggesting that, in WT animals, amylin may play a 
role in the mechanisms leading to chronic neuropathic pain settlement by promoting 
the development of allodynia and hyperalgesia.  
The data from the visceral pain model suggest an anti-nociceptive role of 
amylin in visceral pain as amylin KO mice displayed more pain-related behaviors, 
contracting the abdomen more times. This is in line with reports of antinociceptive 
amylin effects in the same pain model, suggested to be mediated via the spinal cord, 
and further supports an endogenous role for this peptide in the modulation of visceral 
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pain. The c-Fos expression was also higher in the spinal cord of KO animals, supporting 
the behavioral tests results and suggesting that indeed larger amounts of noxious 
information reached the spinal cord in animals lacking amylin expression. 
Taken together, the behavioral tests suggested different roles for amylin as a 
neuropeptide mediator in nociception, being anti-nociceptive in the visceral pain 
model and pro-nociceptive in the neuropathic and inflammatory pain models. In naïve 
mice, amylin displayed a pro-nociceptive role in the cold plate test (cold hyperalgesia) 
and an anti-nociceptive role in mechanical acute pain tests (mechanical allodynia and 
hyperalgesia).   
Amylin KO mice have lower numbers of DRG neuronal cell bodies until around 
birth, suggesting that amylin might act as a growth or neurotropic factor for DRG 
neurons [93]. These amylin effects may influence pathways involved in pain 
processing, so its lack may lead to a misrepresentation of a subgroup of neurons or 
pathways and could therefore explain why adult amylin KO mice are deficient in 
aspects of nociception, as reported before for the formalin test model [2] and in the 
present manuscript. The neuronal quantification in the L4-5 DRGs of amylin KO mice 
and the determination of their cell body areas lead us to conclude that the large-sized 
neurons, known as Aβ, were scarce, while the small-sized neurons, presumably C and 
Aδ fibers, were in tendency more abundant. So, the Aβ neurons may be the neuronal 
population being affected during development in amylin KO mice. Small-sized neurons, 
which seem to be over-represented in amylin KO DRGs, are known to transmit noxious 
stimuli, which may in part explain the increased sensitivity observed by naïve amylin 
KO mice in acute mechanical pain tests. However, it is known that the somatosensory 
system suffers plastic changes under chronic pain conditions, so whether these 
changes are still observed in chronic pain animals is not known and needs to be 
investigated. 
In order to understand amylin’s role as a modulatory neuropeptide, it is 
essential to rescue the phenotype of the amylin KO mice by administering amylin while 
subjecting the animals to the same pain models. The construction of a conditional 
amylin KO mouse, in which the spatial and temporal expression of amylin may be 
controlled, will allow evaluating amylin’s implication on the development of the 
somatosensory system. 
The CGRP-positive neurons quantification revealed that KO mice did not display 
significant alterations in the C-peptidergic population of DRG neurons, suggesting that 
the variations in KO mice pain behavior are not due to C peptidergic fibers, but may be 
caused by a phenotypic switch between A-neuronal types, possibly from Aβ to Aδ 
fibers, as amylin KO mice showed reduced numbers of large area neurons in the DRGs. 
It has been reported that there is a phenotypic switching of CGRP expression in Aβ 
afferents following nerve injury, and that this is a fundamental mechanism for the 
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development of neuropathic tactile allodynia [95]. It would therefore be interesting to 
study whether CGRP expression would be altered in the SNI-model in amylin KO mice. 
To conclude we can say that amylin displays different roles in nociception 
depending on the pain condition and on the nature of the stimulus induced. 
Additionally, we noticed an alteration in neuronal populations in the DRGs of KO mice. 
We also concluded that the variations in KO mice pain behavior are possibly not due to 
C peptidergic fibers but may be caused by a phenotypic switch between neuronal 
types from Aβ to Aδ fibers. 
It is important to increase the number of animals per group of some 
experiments, in order to acquire more representative data regarding the groups’ 
behavior and to allow a more solid statistical analysis. Moreover, it is essential to 
understand which specific fibers are affected by amylin, so we can clarify amylin’s 
mechanisms and pathways involved in nociception. For that it will be important to 
perform additional immunohistochemical stainings of DRG sections with additional 
neuronal markers for A-fibers and C-non-peptidergic neurons. 
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Annexes  
 
Genotyping protocol of mice IAPP 
For the DNA extraction: 
1. Prepare fresh NaOH solution by adding a NaOH pellet in 50mL of H2O 
milliQ 
2. Add 600uL NaOH solution to each tube 
3. Piercing the eppendorf containing mouse tissue fragment 
4. Put at 99 °C for 10min to 1h 
5. Allow to cool 
6. Add 100uL 1M Tris-HCl pH 8.0. 
 
For the PCR reaction (20uL in each tube): 
 
1. H2O    10.9 µL 
2. Taq polimerase Citomed 0.1 µL 
3. Buffer 10x   2 µL 
4. MgSO4   2 µL 
5. Primer 206 10uM  1 µL  
6. Primer 207 10uM  1 µL 
7. Primer 208 10uM  1 µL  
8. Primer 209 10uM  1 µL  
9. Sample DNA   1 µL 
 
Reactions condition: 
95oC 5  min 
95oC 30  sec  
62oC 30  sec      35 cycles 
72oC 30  sec 
72oC 10 min 
 
Electrophoresis in agarose 2% gel  
Results: 
 
- wild-type allele   100bps 
- mutated allele   200bps 
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Complete Freund’s Adjuvant 
In a 50 mL flask place 60 mg of Mycobacterium butyricum and then add (drop by drop 
with agitation): 
1. 6 mL paraffin oil; 
2. 4 mL NaCl 0,9%; 
3. 1 mL Tween 80; 
4. 2.75 mg of azide. 
Autoclave the flask at 121 ºC for 20 minutes. Allow it to cool and place at 4ºC. 
Cryoprotector (1000mL): 
a) 0.4M PBS pH 7.2 - 125mL; 
b) Saccharose (Merck, Darmstadt) – 330 g; 
c) Ethylene glycol (Merck, Darmstadt) - 300 mL; 
d) Make up the volume to 1000 mL with distilled water. 
 
Hydrogen Peroxide 1% (at 1% H2O2): 
a) H2O2 30% (Merck, Darmstadt) - 330μL; 
b) PBS - 10 mL. 
 
Normal swine serum (NSS, Normal English Suine Serum) 2% in PBS / T 0.1M (50mL): 
a) 1 mL of NSS; 
b) Make up to 50 ml with PBS / T 0.1M. 
 
Phosphate buffer (PB) to 0.4M - stock solution (2500mL):  
a) 26.2g of hydrated sodium dihydrogen phosphate (NaH2PO4.H2O; Merck, Darmstadt); 
b) 140g of potassium phosphate (K2HPO4; Merck, Darmstadt); 
c) Dilute a total volume of 2500mL of distilled water; 
d) Check pH (7.2-7.4). 
 
Phosphate Buffered Saline (PBS) 0.1M (1000mL): 
a) Phosphate Buffer - 250 mL; 
b) Distilled water - 750 mL; 
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c) NaCl (Merck, Darmstadt) - 9 g. 
 
Phosphate Buffer Saline with Triton X-100 (PBS / T) 0.1M (1000mL): 
a) Phosphate Buffer - 250 mL; 
b) 3 mL of Triton X-100 or 12 mL solution of 25% Triton X.100; 
c) NaCl - 9 g; 
d) Make up the volume to 1000 mL with distilled water. 
 
0.1M Tris-HCl buffer, pH 7.6: 
a) 0.2M Tris (Merck, Darmstadt) – 12.1g in 500 mL of distilled water; 
b) 1N HCl (Merck, Darmstadt) – 8.3mL in 100 mL of distilled water. 
 
 
